<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5401629 - Assay methods and compositions useful for measuring the transduction of an ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Assay methods and compositions useful for measuring the transduction of an intracellular signal"><meta name="DC.contributor" content="Michael M. Harpold" scheme="inventor"><meta name="DC.contributor" content="Paul Brust" scheme="inventor"><meta name="DC.contributor" content="The Salk Institute Biotechnology/Industrial Associates, Inc." scheme="assignee"><meta name="DC.date" content="1990-8-7" scheme="dateSubmitted"><meta name="DC.description" content="Recombinant cells are provided which are useful for assaying compounds for their agonist or antagonist activity with respect to ion channels and/or cell surface-localized receptors. In addition, assay methods employing the invention recombinant cells are provided."><meta name="DC.date" content="1995-3-28" scheme="issued"><meta name="DC.relation" content="US:4859609" scheme="references"><meta name="DC.relation" content="US:4981784" scheme="references"><meta name="DC.relation" content="US:5071773" scheme="references"><meta name="DC.relation" content="US:5091518" scheme="references"><meta name="citation_reference" content="Allard, et al., &quot;Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor,&quot; Nucl. Acids. Res., 15:10604 (1987)."><meta name="citation_reference" content="Allard, et al., Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor, Nucl. Acids. Res., 15:10604 (1987)."><meta name="citation_reference" content="Alton and Vapnek, &quot;Nucleotide sequence analysis of the chloramphenicol resistance transposon tn9,&quot; Nature, 282:864-869 (1979)."><meta name="citation_reference" content="Alton and Vapnek, Nucleotide sequence analysis of the chloramphenicol resistance transposon tn9, Nature, 282:864 869 (1979)."><meta name="citation_reference" content="Baldwin, et al., &quot;Cloning of the luciferase structural genes from vibrio harveyi and expression of bioluminescence in escherichia coli,&quot; Biochemistry, 23:3663-3667 (1984)."><meta name="citation_reference" content="Baldwin, et al., Cloning of the luciferase structural genes from vibrio harveyi and expression of bioluminescence in escherichia coli, Biochemistry, 23:3663 3667 (1984)."><meta name="citation_reference" content="Bonner, et al., &quot;Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes,&quot; Neuron, 1:403-410 (1988)."><meta name="citation_reference" content="Bonner, et al., Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes, Neuron, 1:403 410 (1988)."><meta name="citation_reference" content="Boulter, et al., &quot;Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor α-subunit,&quot; Nature, 319:368-374 (1986)."><meta name="citation_reference" content="Boulter, et al., &quot;α3, α5, and β4: Three members of the rat neuronal nicotinic acetylcholine receptor-related gene family form a gene cluster,&quot; J. Biol. Chem., 265:4472-4482 (1990)."><meta name="citation_reference" content="Boulter, et al., 3, 5, and 4: Three members of the rat neuronal nicotinic acetylcholine receptor related gene family form a gene cluster, J. Biol. Chem., 265:4472 4482 (1990)."><meta name="citation_reference" content="Boulter, et al., Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor subunit, Nature, 319:368 374 (1986)."><meta name="citation_reference" content="Bunzow, et al., &quot;Cloning and expression of a rat D2 dopamine receptor cDNA,&quot; Nature, 336:783-787 (1988)."><meta name="citation_reference" content="Bunzow, et al., Cloning and expression of a rat D 2 dopamine receptor cDNA, Nature, 336:783 787 (1988)."><meta name="citation_reference" content="Changelian, et al., &quot;Structure of the NGFI-A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor,&quot; Proc. Natl. Acad. Sci., 86:377-381 (1989)."><meta name="citation_reference" content="Changelian, et al., Structure of the NGFI A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor, Proc. Natl. Acad. Sci., 86:377 381 (1989)."><meta name="citation_reference" content="Collins et al., Proc. Natl. Acad. Sci. USA, vol. 86., (Jul. 1989), pp.  484857."><meta name="citation_reference" content="Collins et al., Proc. Natl. Acad. Sci. USA, vol. 86., (Jul. 1989), pp. 4853 4857."><meta name="citation_reference" content="Comb, et al., &quot;A cyclic AMP- and phorbol ester-inducible DNA element,&quot; Nature, 323:353-356 (1986)."><meta name="citation_reference" content="Comb, et al., A cyclic AMP and phorbol ester inducible DNA element, Nature, 323:353 356 (1986)."><meta name="citation_reference" content="Deneris, et al., &quot;Primary structure and expression of β2: A novel subunit of neuronal nicotinic acetylcholine receptors,&quot; Neuron, 1:45-54 (1988)."><meta name="citation_reference" content="Deneris, et al., &quot;β3 : A new member of nicotinic acetylcholine receptor gene family is expressed in brain,&quot; J. Biol. Chem., 264:6268-6272 (1989)."><meta name="citation_reference" content="Deneris, et al., 3 : A new member of nicotinic acetylcholine receptor gene family is expressed in brain, J. Biol. Chem., 264:6268 6272 (1989)."><meta name="citation_reference" content="Deneris, et al., Primary structure and expression of 2: A novel subunit of neuronal nicotinic acetylcholine receptors, Neuron, 1:45 54 (1988)."><meta name="citation_reference" content="Deschamps, et al., &quot;Identification of a transcriptional enhancer element upstream from the proto-oncogen fos,&quot; Science, 230:1174-1177 (1985)."><meta name="citation_reference" content="Deschamps, et al., Identification of a transcriptional enhancer element upstream from the proto oncogen fos, Science, 230:1174 1177 (1985)."><meta name="citation_reference" content="deWet, et al., &quot;Firefly luciferase gene: structure and expression in mammalian cells,&quot; Mol. Cell. Biol. 7:725-737 (1987)."><meta name="citation_reference" content="deWet, et al., Firefly luciferase gene: structure and expression in mammalian cells, Mol. Cell. Biol. 7:725 737 (1987)."><meta name="citation_reference" content="Dixon, et al., &quot;Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin,&quot; Nature, 321:75-79 (1986)."><meta name="citation_reference" content="Dixon, et al., Cloning of the gene and cDNA for mammalian adrenergic receptor and homology with rhodopsin, Nature, 321:75 79 (1986)."><meta name="citation_reference" content="Duvoisin, et al., &quot;The functional diversity of the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: β4,&quot; Neuron, 3:487-496 (1989)."><meta name="citation_reference" content="Duvoisin, et al., The functional diversity of the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: 4, Neuron, 3:487 496 (1989)."><meta name="citation_reference" content="Ellis, et al., &quot;Sequence and expression of mRNAS encoding the α1 and α2 subunits of a DHP-sensitive calcium channel,&quot; Science, 241:1661-1664 (1988)."><meta name="citation_reference" content="Ellis, et al., Sequence and expression of mRNAS encoding the 1 and 2 subunits of a DHP sensitive calcium channel, Science, 241:1661 1664 (1988)."><meta name="citation_reference" content="Engebrecht and Silverman, &quot;Identification of genes and gene products necessary for bacterial bioluminescence,&quot; PNAS, 1:4154-4158 (1984)."><meta name="citation_reference" content="Engebrecht and Silverman, Identification of genes and gene products necessary for bacterial bioluminescence, PNAS, 1:4154 4158 (1984)."><meta name="citation_reference" content="Fink, et al., &quot;The CGTCA sequence motif is essential for biological activity of the vasoactive intestinal peptide gene cAMP-regulated enhancer,&quot; Proc. Natl. Acad. Sci., 85:6662-6666 (1988)."><meta name="citation_reference" content="Fink, et al., The CGTCA sequence motif is essential for biological activity of the vasoactive intestinal peptide gene cAMP regulated enhancer, Proc. Natl. Acad. Sci., 85:6662 6666 (1988)."><meta name="citation_reference" content="Frielle, et al., &quot;Cloning of the cDNA for the human β1 -adrenergic receptor,&quot; PNAS, 84:7920-7924 (1987)."><meta name="citation_reference" content="Frielle, et al., Cloning of the cDNA for the human 1 adrenergic receptor, PNAS, 84:7920 7924 (1987)."><meta name="citation_reference" content="Goldman, et al., &quot;Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system,&quot; Cell, 48:965-973 (1987)."><meta name="citation_reference" content="Goldman, et al., Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system, Cell, 48:965 973 (1987)."><meta name="citation_reference" content="Hollmann, et al., &quot;Cloning by functional expression of a member of the glutamate receptor family,&quot; Nature, 342:643-648 (1989)."><meta name="citation_reference" content="Hollmann, et al., Cloning by functional expression of a member of the glutamate receptor family, Nature, 342:643 648 (1989)."><meta name="citation_reference" content="Horowitz, et al., &quot;Muscarinic receptor stimulation increases inositol-phospholipid metabolism and inhibits cyclic AMP accumulation in PC12 cells,&quot; J. Neurochem., 53:197-204 (1989)."><meta name="citation_reference" content="Horowitz, et al., Muscarinic receptor stimulation increases inositol phospholipid metabolism and inhibits cyclic AMP accumulation in PC12 cells, J. Neurochem., 53:197 204 (1989)."><meta name="citation_reference" content="Jay, et al., &quot;Primary structure of the γ subunit of the DHP-sensitive calcium channel from skeletal muscle,&quot; Science, 248:490-492 (1990)."><meta name="citation_reference" content="Jay, et al., Primary structure of the subunit of the DHP sensitive calcium channel from skeletal muscle, Science, 248:490 492 (1990)."><meta name="citation_reference" content="Johnson, et al., &quot;Expression and structure of the human NGF receptor,&quot; Cell, 47:545-554 (1986)."><meta name="citation_reference" content="Johnson, et al., Expression and structure of the human NGF receptor, Cell, 47:545 554 (1986)."><meta name="citation_reference" content="Julius, et al., &quot;Molecular characterization of a functional cDNA encoding the serotonin 1c receptor,&quot; Science, 241:558-564 (1988)."><meta name="citation_reference" content="Julius, et al., &quot;The 5HT2 receptor defines a family of structurally distnict but functionally conserved serotonin receptors,&quot; PNAS, 87:928-932 (1990)."><meta name="citation_reference" content="Julius, et al., Molecular characterization of a functional cDNA encoding the serotonin 1c receptor, Science, 241:558 564 (1988)."><meta name="citation_reference" content="Julius, et al., The 5HT2 receptor defines a family of structurally distnict but functionally conserved serotonin receptors, PNAS, 87:928 932 (1990)."><meta name="citation_reference" content="Kayano, et al., &quot;Primary structure of rat brain sodium channel III deduced from the cDNA sequence,&quot; FEBS Lett., 228:187-194 (1988)."><meta name="citation_reference" content="Kayano, et al., Primary structure of rat brain sodium channel III deduced from the cDNA sequence, FEBS Lett., 228:187 194 (1988)."><meta name="citation_reference" content="Kobilka, et al., &quot;An intronless gene encoding a potential member of the fmaily of receptors coupled to guanine nucleotide regulatory proteins,&quot; Nature, 329:75-79 (1987)."><meta name="citation_reference" content="Kobilka, et al., &quot;Cloning, sequencing, and expression of the gene coding for the human platelet α2 -adrenergic receptor,&quot; Science, 238:650-656 (1987)."><meta name="citation_reference" content="Kobilka, et al., An intronless gene encoding a potential member of the fmaily of receptors coupled to guanine nucleotide regulatory proteins, Nature, 329:75 79 (1987)."><meta name="citation_reference" content="Kobilka, et al., Cloning, sequencing, and expression of the gene coding for the human platelet 2 adrenergic receptor, Science, 238:650 656 (1987)."><meta name="citation_reference" content="Lamb, et al., &quot;Demonstration in living cells of an intragenic negative regulatory element within the rodent c-fos gene,&quot; Cell, 61:485-496 (1990)."><meta name="citation_reference" content="Lamb, et al., Demonstration in living cells of an intragenic negative regulatory element within the rodent c fos gene, Cell, 61:485 496 (1990)."><meta name="citation_reference" content="Lambert, et al., &quot;Muscarinic receptor binding characteristics of a human neuroblastomas SK-N-SH and its clones SH-SY5Y and SH-EP1,&quot; Eur. J. Pharmacol., 165:71-77 (1988)."><meta name="citation_reference" content="Lambert, et al., Muscarinic receptor binding characteristics of a human neuroblastomas SK N SH and its clones SH SY5Y and SH EP1, Eur. J. Pharmacol., 165:71 77 (1988)."><meta name="citation_reference" content="Levitan, et al., &quot;Structural and functional basis for GABAA receptor heterogeneity,&quot; Nature, 335:76-79 (1988)."><meta name="citation_reference" content="Levitan, et al., Structural and functional basis for GABA A receptor heterogeneity, Nature, 335:76 79 (1988)."><meta name="citation_reference" content="McKinnon, D., &quot;Isolation of a cDNA clone coding for a putative second potassium channel indicates the existence of a gene family,&quot; J. Biol. Chem., 264:8230-8236 (1989)."><meta name="citation_reference" content="McKinnon, D., Isolation of a cDNA clone coding for a putative second potassium channel indicates the existence of a gene family, J. Biol. Chem., 264:8230 8236 (1989)."><meta name="citation_reference" content="Michel, et al., &quot;PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site,&quot; Br. J. Pharmacol., 97:914-920 (1989)."><meta name="citation_reference" content="Michel, et al., PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site, Br. J. Pharmacol., 97:914 920 (1989)."><meta name="citation_reference" content="Montminy, et al., &quot;Identification of a cyclic-AMP-responsive element within the rat somatostatin gene,&quot; Proc. Natl. Acad. Sci., 83:6682-6686 (1986)."><meta name="citation_reference" content="Montminy, et al., Identification of a cyclic AMP responsive element within the rat somatostatin gene, Proc. Natl. Acad. Sci., 83:6682 6686 (1986)."><meta name="citation_reference" content="Noda, et al., &quot;Existence of distinct sodium channel messenger RNAs in rat brain,&quot; Nature, 320:188-192 (1986)."><meta name="citation_reference" content="Noda, et al., Existence of distinct sodium channel messenger RNAs in rat brain, Nature, 320:188 192 (1986)."><meta name="citation_reference" content="Peralta, et al., &quot;Differential regulation of PI hydrolysis and adenylyl cyclase by mascarinic receptor subtypes,&quot; Nature, 334:434-437 (1988)."><meta name="citation_reference" content="Peralta, et al., Differential regulation of PI hydrolysis and adenylyl cyclase by mascarinic receptor subtypes, Nature, 334:434 437 (1988)."><meta name="citation_reference" content="Pritchett, et al., &quot;Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology,&quot; Nature, 338:582-585 (1989)."><meta name="citation_reference" content="Pritchett, et al., Importance of a novel GABA A receptor subunit for benzodiazepine pharmacology, Nature, 338:582 585 (1989)."><meta name="citation_reference" content="Ruth, et al., &quot;Primary structure of the β subunit of the DHP-sensitive calcium channel from skeletal muscle,&quot; Science, 245:1115-1118 (1989)."><meta name="citation_reference" content="Ruth, et al., Primary structure of the subunit of the DHP sensitive calcium channel from skeletal muscle, Science, 245:1115 1118 (1989)."><meta name="citation_reference" content="Schofield, et al., &quot;Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family,&quot; Nature, 328:221-227 (1987)."><meta name="citation_reference" content="Schofield, et al., Sequence and functional expression of the GABA A receptor shows a ligand gated receptor super family, Nature, 328:221 227 (1987)."><meta name="citation_reference" content="Serra, et al., &quot;Phorbol esters alter muscarinic receptor binding and inhibit polyphosphoninositide breakdown in human neuroblastoma (SH-SY5Y) cells,&quot; Biochem. Biophys. Res. Comm., 140:160-166 (1988)."><meta name="citation_reference" content="Serra, et al., &quot;The intact human neuroblastoma cell (SH-SY5Y) exhibits high-affinity [3 H]pirenzepine binding associated with hydrolysis of phosphatidylinositols,&quot; J. Neurochem., 50:1513-1521 (1988)."><meta name="citation_reference" content="Serra, et al., Phorbol esters alter muscarinic receptor binding and inhibit polyphosphoninositide breakdown in human neuroblastoma (SH SY5Y) cells, Biochem. Biophys. Res. Comm., 140:160 166 (1988)."><meta name="citation_reference" content="Serra, et al., The intact human neuroblastoma cell (SH SY5Y) exhibits high affinity 3 H pirenzepine binding associated with hydrolysis of phosphatidylinositols, J. Neurochem., 50:1513 1521 (1988)."><meta name="citation_reference" content="Sheng, et al., &quot;The regulation and function of c-fos and other immediate early genes in the nervous system,&quot; Neuron, 4:477-485 (1990)."><meta name="citation_reference" content="Sheng, et al., The regulation and function of c fos and other immediate early genes in the nervous system, Neuron, 4:477 485 (1990)."><meta name="citation_reference" content="Shivers, B. D., &quot;Two novel GABAA receptor subunits exist in distinct neuronal subpopulations,&quot; Neuron, 3:327-337 (1989)."><meta name="citation_reference" content="Shivers, B. D., Two novel GABA A receptor subunits exist in distinct neuronal subpopulations, Neuron, 3:327 337 (1989)."><meta name="citation_reference" content="Short, et al., &quot;Characterization of the phosphoenolpyruvate carboxykinase (GTP) promoter-regulatory region,&quot; J. Biol. Chem., 261:9721-9726 (1986)."><meta name="citation_reference" content="Short, et al., Characterization of the phosphoenolpyruvate carboxykinase (GTP) promoter regulatory region, J. Biol. Chem., 261:9721 9726 (1986)."><meta name="citation_reference" content="Stormann, et al., &quot;Molecular cloning and expression of a dopamine D2 receptor from human retina,&quot; Molec. Pharm. 37:1-6 (1990)."><meta name="citation_reference" content="Stormann, et al., Molecular cloning and expression of a dopamine D2 receptor from human retina, Molec. Pharm. 37:1 6 (1990)."><meta name="citation_reference" content="Subramani, et al., &quot;Expression of the mouse dihydrofolate complementary deoxyribonucleic reductase acid in simian virus 40,&quot; Mol. Cell. Biol., 1:854-864 (1981)."><meta name="citation_reference" content="Subramani, et al., Expression of the mouse dihydrofolate complementary deoxyribonucleic reductase acid in simian virus 40, Mol. Cell. Biol., 1:854 864 (1981)."><meta name="citation_reference" content="Tanabe, et al., &quot;Primary structure of the receptor for calcium channel b lockers from skeletal muscle,&quot; Nature, 328:313-318 (1987)."><meta name="citation_reference" content="Tanabe, et al., Primary structure of the receptor for calcium channel b lockers from skeletal muscle, Nature, 328:313 318 (1987)."><meta name="citation_reference" content="Tempel, et al., &quot;Cloning of a probable potassium channel gene from mouse brain,&quot; Nature, 332:837-839 (1988)."><meta name="citation_reference" content="Tempel, et al., Cloning of a probable potassium channel gene from mouse brain, Nature, 332:837 839 (1988)."><meta name="citation_reference" content="Toh, et al., &quot;Isolation and characterization of a rat liver alkaline phosphatase gene,&quot; Eur. J. Biochem., 182:231-238 (1989)."><meta name="citation_reference" content="Toh, et al., Isolation and characterization of a rat liver alkaline phosphatase gene, Eur. J. Biochem., 182:231 238 (1989)."><meta name="citation_reference" content="Verma, et al., &quot;Proto-Oncogene fos: Complex but versatile regulation,&quot; Cell, 51:513-514 (1987)."><meta name="citation_reference" content="Verma, et al., Proto Oncogene fos: Complex but versatile regulation, Cell, 51:513 514 (1987)."><meta name="citation_reference" content="Visvader, et al., &quot;Two adjacent promoter elements mediate nerve growth factor activation of the c-fos gene and bind distinct nuclear complexes,&quot; PNAS, 85:9474-9478 (1988)."><meta name="citation_reference" content="Visvader, et al., Two adjacent promoter elements mediate nerve growth factor activation of the c fos gene and bind distinct nuclear complexes, PNAS, 85:9474 9478 (1988)."><meta name="citation_reference" content="Wada, et al., &quot;Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor,&quot; Science, 240:330-334 (1988)."><meta name="citation_reference" content="Wada, et al., Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor, Science, 240:330 334 (1988)."><meta name="citation_reference" content="Ymer, et al., &quot;GABAA receptor β subunit heterogeneity: functional expression of cloned cDNAs,&quot; EMBO J., 8:1665-1670 (1989)."><meta name="citation_reference" content="Ymer, et al., GABA A receptor subunit heterogeneity: functional expression of cloned cDNAs, EMBO J., 8:1665 1670 (1989)."><meta name="citation_patent_number" content="US:5401629"><meta name="citation_patent_application_number" content="US:07/563,751"><link rel="canonical" href="http://www.google.com/patents/US5401629"/><meta property="og:url" content="http://www.google.com/patents/US5401629"/><meta name="title" content="Patent US5401629 - Assay methods and compositions useful for measuring the transduction of an intracellular signal"/><meta name="description" content="Recombinant cells are provided which are useful for assaying compounds for their agonist or antagonist activity with respect to ion channels and/or cell surface-localized receptors. In addition, assay methods employing the invention recombinant cells are provided."/><meta property="og:title" content="Patent US5401629 - Assay methods and compositions useful for measuring the transduction of an intracellular signal"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("fSXuU87HKLjMsQTI0IL4Ag"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("POL"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("fSXuU87HKLjMsQTI0IL4Ag"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("POL"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5401629?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5401629"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=yYc7BAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5401629&amp;usg=AFQjCNE1E1v01vwmEWI1MpLmXg09PX_GDA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5401629.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5401629.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5401629" style="display:none"><span itemprop="description">Recombinant cells are provided which are useful for assaying compounds for their agonist or antagonist activity with respect to ion channels and/or cell surface-localized receptors. In addition, assay methods employing the invention recombinant cells are provided....</span><span itemprop="url">http://www.google.com/patents/US5401629?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5401629 - Assay methods and compositions useful for measuring the transduction of an intracellular signal</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5401629 - Assay methods and compositions useful for measuring the transduction of an intracellular signal" title="Patent US5401629 - Assay methods and compositions useful for measuring the transduction of an intracellular signal"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5401629 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 07/563,751</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Mar 28, 1995</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Aug 7, 1990</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Aug 7, 1990</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Lapsed</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2087532A1">CA2087532A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2087532C">CA2087532C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69133452D1">DE69133452D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69133452T2">DE69133452T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0542830A1">EP0542830A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0542830A4">EP0542830A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0542830B1">EP0542830B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0542830B2">EP0542830B2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1586658A2">EP1586658A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1586658A3">EP1586658A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5436128">US5436128</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1992002639A1">WO1992002639A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">07563751, </span><span class="patent-bibdata-value">563751, </span><span class="patent-bibdata-value">US 5401629 A, </span><span class="patent-bibdata-value">US 5401629A, </span><span class="patent-bibdata-value">US-A-5401629, </span><span class="patent-bibdata-value">US5401629 A, </span><span class="patent-bibdata-value">US5401629A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Michael+M.+Harpold%22">Michael M. Harpold</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Paul+Brust%22">Paul Brust</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22The+Salk+Institute+Biotechnology/Industrial+Associates,+Inc.%22">The Salk Institute Biotechnology/Industrial Associates, Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5401629.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5401629.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5401629.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (4),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (110),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (138),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (19),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (11)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5401629&usg=AFQjCNFdj3Z-7OetspwBxmujU45QF7eLwg">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5401629&usg=AFQjCNH5eK3jaEbRuCQ1N-SqnENQIF3mWg">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5401629A%26KC%3DA%26FT%3DD&usg=AFQjCNFMbXDeW9uORF4vfWX99QSlnHYs4A">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT53935724" lang="EN" load-source="patent-office">Assay methods and compositions useful for measuring the transduction of an intracellular signal</invention-title></span><br><span class="patent-number">US 5401629 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37412378" lang="EN" load-source="patent-office"> <div class="abstract">Recombinant cells are provided which are useful for assaying compounds for their agonist or antagonist activity with respect to ion channels and/or cell surface-localized receptors. In addition, assay methods employing the invention recombinant cells are provided.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(17)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5401629-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5401629-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(14)</span></span></div><div class="patent-text"><div mxw-id="PCLM4839260" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>That which is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method for identifying compounds that modulate cell surface protein-mediated activity by detecting intracellular transduction of a signal generated upon interaction of the compound with the cell surface protein, comprising:<div class="claim-text">comparing the amount of transcription of a reporter gene or the amount of reporter gene product expressed in a first recombinant cell in the presence of the compound with the amount of transcription or product in the absence of the compound, or with the amount of transcription or product in a second recombinant cell; and</div> <div class="claim-text">selecting compounds that change the amount of transcription of a reporter gene or the amount of reporter gene product expressed in the first recombinant cell in the presence of the compound compared to the amount of transcription or product in the absence of the compound, or compared to the amount of transcription or product in the second recombinant cell, wherein:</div> <div class="claim-text">the cell surface protein is a surface receptor or ion channel;</div> <div class="claim-text">the first recombinant cell contains a reporter gene Construct and expresses the cell surface protein;</div> <div class="claim-text">the second recombinant cell is identical to the first recombinant cell, except that it does not express the cell surface protein; and</div> <div class="claim-text">the reporter gene constructs contains:<div class="claim-text">(a) a transcriptional control element that is responsive to the intracellular signal that is generated by the interaction of an agonist with the cell surface protein; and</div> <div class="claim-text">(b) a reporter gene that encodes a detectable transcriptional or translational product and that is in operative association with the transcriptional control element.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The method of claim 1, wherein said compound is an agonist or antagonist of said cell surface receptor or ion channel.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The method of claim 1, wherein the amount of transcription is determined by measuring the amount of mRNA that is transcribed from said reporter gene.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The method of claim 1, wherein the amount of transcription is measured by measuring the amount of reporter gene protein that is produced.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The method of claim 2, wherein said compound is an antagonist.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The method of claim 2, further comprising, prior to comparing the difference in the amount of transcription of the reporter gene, contacting the recombinant cell with an agonist that activates said cell surface protein, whereby transcription of said reporter gene is induced.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The method of claim 1, wherein said reporter gene construct includes a transcriptional regulatory region that includes a sequence of nucleotides that modulates transcription from said promoter in the absence of said cell surface protein or compound.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The method of claim 1, wherein the transcriptional control element includes a promoter selected from the group consisting of the c-fos gene promoter, the vasoactive intestinal peptide gene promoter, the somatostatin gene promoter, the proenkephalin gene promoter, the phosphoenolpyruvate carboxykinase gene promoter and the nerve growth factor-1 A gene promoter.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The method of claim 1, wherein the reporter gene is selected from the group consisting of the gene encoding bacterial chloramphenicol acetyltransferase, the gene encoding firefly luciferase, the gene encoding bacterial luciferase, and the gene encoding alkaline phosphatase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 1, wherein the transcriptional control region includes at least one regulatory element selected from the group consisting of serum responsive elements, cyclic adenosine monophosphate responsive elements, and elements responsive to intracellular calcium ion levels.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The method of claim 1, wherein the cell surface receptor is the Type 1 human muscarinic receptor, the promoter is the c-fos promoter and the reporter gene is the gene encoding bacterial chloramphenicol acetyltransferase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. The method of claim 1, wherein the cell surface receptor is selected from the group consisting of muscarinic receptors, neuronal nicotinic acetylcholine receptors, gamma aminobutyric acid receptors, glutamate receptors, adrenergic receptors, dopamine receptors, nerve growth factor receptors, and serotonin receptors.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. The method of claim 1, wherein the ion channel is a calcium channel, potassium ion channel, or a sodium ion channel.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. The method of claim 6, wherein said compound is an antagonist.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66656686" lang="EN" load-source="patent-office" class="description">
    <heading>FIELD OF THE INVENTION</heading> <p>The present invention relates to methods and compositions useful for assaying the transduction of an intracellular signal in cells expressing cell surface-localized receptors and/or ion channels. In a particular aspect, the present invention relates to methods for assaying the agonist or antagonist activity of compounds with respect to cell surface-localized receptors and/or ion channels.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>Ion channels are membrane spanning proteins that allow controlled entry of various ions into cells from the extracellular fluid. All cells throughout the animal kingdom, as well as most bacterial, fungal, and plant cells, possess one or more types of ion channel. Similarly, cell surface-localized receptors control entry of various chemical species into cells from the extracellular fluid. As with ion channels, cell surface-localized receptors are found in nearly all members of the plant and animal kingdoms. Ion channels and cell surface-localized receptors are physiologically important, playing a central role in regulating intracellular levels of various ions and chemicals, many of which are important for cell viability and function.</p>
    <p>A number of compounds useful in treating various diseases in animals, including humans, are thought to exert their beneficial effects by modulating the functioning of ion channels and/or cell surface-localized receptors.</p>
    <p>An understanding of the pharmacology of compounds that interact with ion channels and/or cell-surface localized receptors, and the ability to rationally design compounds that will interact with ion channels and/or cell surface-localized receptors to have desired therapeutic effects, have been hampered by the lack of rapid, effective means to identify those compounds which interact with specific ion channels and/or specific cell surface-localized receptors.</p>
    <p>The availability of rapid, effective means to identify compounds which interact with ion channels and/or cell surface-localized receptors would enable the rapid screening of a large number of compounds to identify those candidates suitable for further, in-depth studies of therapeutic applications.</p>
    <p>The availability of rapid, effective means to determine if cells are producing functional ion channels and/or cell surface-localized receptors of a specific type would enable the rapid screening of cells for the presence of functional ion channels and/or surface-localized receptors that control passage across the cell membrane.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>In accordance with the present invention, there are provided novel recombinant cells which are useful for assaying compounds for their agonist or antagonist activity with respect to specific ion channels and/or specific cell surface localized receptors. In addition, assay methods employing the invention recombinant cells are provided.</p>
    <p>The invention assay methods provide rapid, reliable methods to identify compounds which interact with, and thereby affect the function of, specific ion channels and/or specific cell surface-localized receptors; as well as rapid reliable methods to determine if cells are producing specific functional ion channels and/or cell specific functional surface-localized receptors.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>In accordance with the present invention, there is provided a recombinant cell useful for assaying compounds to determine the agonist or antagonist activity of such compounds with respect to receptors of a specific type; wherein said receptors are present on the surface of said cell; and wherein said cell is transformed with a reporter gene construct comprising:</p>
    <p>a transcriptional control element which is responsive to an intracellular condition that occurs when said receptor interacts with a compound having agonist or antagonist activity with respect to said receptor, and</p>
    <p>a reporter gene encoding a transcriptional and/or translational product; wherein said product can, directly or indirectly, be readily measured; and wherein said gene is in operative association with said transcriptional control element.</p>
    <p>In accordance with another embodiment of the present invention, there is provided a method to assay compounds to determine the cell receptor agonist or antagonist activity thereof, said method comprising:</p>
    <p>determining the level of the transcriptional and/or translational products of the reporter gene which is produced when a recombinant cell useful for assaying compounds (as described above; sometimes referred to herein as "receptor assay cell") is challenged with media containing the test compound, relative to the level of the transcriptional and/or translational products of the reporter gene which is produced when a negative control cell is challenged with media containing the test compound; wherein the negative control cell is identical to the receptor assay cell described above, except the negative control cell does not express the specific receptor type which is present on the surface of the receptor assay cell.</p>
    <p>In accordance with yet another embodiment of the present invention, there is provided an alternate method to assay compounds to determine the cell receptor agonist or antagonist activity thereof, said method comprising:</p>
    <p>determining the level of the transcriptional and/or translational products of the reporter gene which is produced when a receptor assay cell (as described above) is challenged with media containing the test compound, relative to the level of the transcriptional and/or translational products of the reporter gene which is produced when said receptor assay cell is challenged with control media not containing the test compound.</p>
    <p>In accordance with still another embodiment of the present invention, there is provided a recombinant cell useful for assaying compounds to determine the agonist or antagonist activity of said compounds with respect to ion channels of a specific type; wherein said ion channels are present on the surface of said cell; and wherein said cell is transformed with a reporter gene construct comprising:</p>
    <p>a transcriptional control element which is responsive to an intracellular condition that occurs when said ion channel interacts with a compound having agonist or antagonist activity with respect to said ion channel, and</p>
    <p>a reporter gene encoding a transcriptional and/or translational product; wherein said product can, directly or indirectly, be readily measured; and wherein said gene is in operative association with said transcriptional control element.</p>
    <p>In accordance with a further embodiment of the present invention, there is provided a method to assay compounds to determine the ion channel agonist or antagonist activity thereof, said method comprising:</p>
    <p>determining the level of the transcriptional and/or translational products of said reporter gene which is produced when a recombinant cell (as described above; sometimes referred to herein as "ion channel assay cell") is challenged with media containing the test compound, relative to the level of the transcriptional and/or translational products of the reporter gene which is produced when a negative control cell is challenged with media containing the test compound; wherein said negative control cell is identical to said ion channel assay cell (as described above) except said negative control cell does not express the specific ion channel which is present on the surface of the ion channel assay cell.</p>
    <p>In accordance with a still further embodiment of the present invention, there is provided an alternate method to assay compounds to determine the ion channel agonist or antagonist activity thereof, said method comprising:</p>
    <p>determining the level of the transcriptional and/or translational products of said reporter gene which is produced when an ion channel assay cell (as described above) is challenged with media containing the test compound, relative to the level of the transcriptional and/or translational products of the reporter gene which is produced when said cell is challenged with media which does not contain said test compound.</p>
    <p>In accordance with the present invention, the level of reporter gene product expressed as a result of exposing a receptor or ion channel assay cell to a test compound is measured and compared to the level of reporter gene product expressed by a negative control cell, or compared to the level induced (in a cell of the invention) by a control (rather than test) compound. The intracellular signal to be transduced and, ultimately, measured, is generally initiated by a ligand interacting with a specific receptor or specific ion channel present on the cell surface. This interaction sets in motion a cascade of intracellular events, the ultimate consequence of which is a measurable change in transcription and/or translation of the reporter gene. An assay that provides a rapid indication of whether a specific receptor or ion channel, expressed on the surface of an eukaryotic cell, interacts with a test compound in a way that influences (either in a positive or negative manner) transduction of the intracellular cascade of events, and thus expression of the reporter gene, would provide a valuable screening tool for the development of compounds that act as agonists or antagonists of a cell receptor or ion channel.</p>
    <p>The assays of this invention measure the end stage of the above described cascade of events, i.e., gene expression. This is accomplished through the use of a reporter gene expression construct which comprises a transcriptional control element and a reporter gene. The transcriptional control element is responsive to an intracellular condition that occurs when the cell receptor or ion channel of a specific type interacts with a compound having agonist or antagonist properties with respect to said receptor or ion channel. The reporter gene is placed in operational association with the transcriptional control element. The appearance of reporter gene product then serves as a readily observed indication of transcription, i.e., the reporter gene is selected from among those genes which encode a protein whose presence or absence is easily measurable.</p>
    <p>The reporter gene expression construct is inserted into an eukaryotic cell which has present on its surface a receptor or ion channel of a specific type. The cell is then contacted with a test compound that may interact with the receptor or ion channel to initiate the intracellular cascade. If such interaction and cascade initiation occurs, the transcriptional control element responds to the specific intracellular alteration, resulting in an increase or decrease in transcription of the reporter gene. The reporter gene product is then assayed, the result of which is an indirect indication of the functional nature of the receptor- or ion channel-ligand interaction.</p>
    <p>The assay of this invention is useful for determining functional ligand-receptor or ligand-ion channel interactions for at least three categories of cell surface-localized receptors which are presently known, i.e., ligand-gated ion channels and voltage-gated ion channels, and G protein-coupled receptors. Examples of each group include:</p>
    <p>ligand-gated ion channels: nicotinic acetylcholine receptors, GABA (gamma-aminobutyric acid) receptors, excitatory receptors (e.g., glutamate and aspartate), and the like;</p>
    <p>voltage-gated ion channels: calcium channels, potassium channels, sodium channels and the like;</p>
    <p>G protein-coupled receptors: adrenergic receptors, muscarinic receptors and the like.</p>
    <p>The invention assay is also useful for determining functional ligand-receptor interactions in cells containing a NMDA (N-methyl-D-aspartate) receptor, which has recently been categorized as being a ligand-gated, voltage-dependent ion channel.</p>
    <p>Interaction of ligand with different members of each category of receptors and ion channels initiates a characteristic cascade of intracellular responses for members of that category. However, the specific responses exhibited by each group member are unique to that member. For instance, in the G-protein coupled receptor category, interactions of a ligand with a muscarinic acetylcholine receptor subtype initiates a cascade of events that begins with G-protein activation and ends with an alteration of cAMP level that influences gene expression. However, the specific influence on gene expression is unique to the specific G-protein-linked receptor in question, i.e., activation of human M1 receptors results in hydrolysis of phosphoinositols, whereas activation of human M3 receptors results in inhibition of adenylate cyclase. If a human M1 receptor-expressing cell also contains a reporter gene expression construct of this invention, then an appropriate transcriptional control element would be one which is capable of responding to the hydrolysis of phosphoinositols; and the reporter gene, functionally associated therewith, will be transcribed upon hydrolysis of phosphoinositol. Assay of the cells for the reporter gene product (directly or indirectly), and a comparison of the result with that from a negative control cell, or a control assay, provides a rapid indication as to the functional nature of the interaction of the human M1 receptor expressed on the cell with a test compound.</p>
    <p>Likewise, functional interaction of a test compound with a voltage-gated calcium channel on a cell can be deduced by measuring the change in the level of reporter gene product which results when the intracellular calcium concentration is altered as a consequence of contacting the ion channel with a test compound that is an agonist or antagonist for this ion channel.</p>
    <p>An example of a suitable transcriptional control element is the c-fos promoter which has elements therein which respond to, for example, calcium, cAMP (cyclic adenosine monophosphate), and NGF (nerve growth factor). An example of a reporter gene is CAT (chloramphenicol acetyl transferase), luciferase, and other enzyme detection systems, such as alkaline phosphatase, beta-galactosidase, and the like.</p>
    <p>Other examples of transcriptional control elements contemplated for use in the practice of the present invention include the vasoactive intestinal peptide gene promoter (cAMP responsive), the somatostatin gene promoter (cAMP responsive), the proenkephalin promoter (responsive to cAMP, nicotinic agonists, and phorbol esters), the phosphoenolpyruvate carboxykinase gene promoter (cAMP responsive), the NGFI-A gene promoter (responsive to NGF, cAMP, and serum), and the like.</p>
    <p>The development of cells which express a receptor or ion channel and a reporter gene expression construct, and which are useful for assay of compounds to determine their agonist or antagonist activity, is exemplified in the Examples provided herewith by reference to mammalian Ltk<sup>-</sup> cell lines which express the Type 1 human muscarinic (HM1) receptor and are transformed with a c-fos-CAT reporter gene expression construct. Those of skill in the art recognize that any cell line capable of transfection, and having low to no background level of the specific receptor or ion channel to be used in the invention assay is acceptable.</p>
    <p>Similar receptor- or ion channel-expressing cell lines can be developed using, for example, the following receptor- or ion channel-encoding DNAs, transcriptional control elements, and reporter genes.</p>
    <p>Exemplary receptors, in addition to those described above, include muscarinic receptors (e.g., human M2 (GenBank accession #M16404); rat M3 (GenBank accession #M16407); human M4 (GenBank accession M16405); human M5 (Bonner et al. (1988) Neuron 1:403-410); and the like); neuronal nicotinic acetylcholine receptors (e.g., the α<sub>2</sub>, α<sub>3</sub> and β<sub>2</sub> subtypes disclosed in U.S. Ser. No. 504,455 (filed Apr. 3, 1990), hereby expressly incorporated by reference herein in its entirety); the rat α2 subunit (Wada et al. (1988) Science 240:330-334); the rat α3 subunit (Boulter et al. (1986) Nature 319:368-374); the rat α4 subunit (Goldman et al. (1987) Cell 48:965-973); the rat α5 subunit (Boulter et al. (1990) J. Biol. Chem. 265:4472-4482); the rat β2 subunit (Deneris et al. (1988) Neuron 1:45-54); the rat β3 subunit (Deneris et al. (1989) J. Biol. Chem. 264: 6268-6272); the rat β4 subunit (Duvoisin et al. (1989) Neuron 3:487-496); and the like); GABA receptors (e.g., the bovine α<sub>1</sub> and β<sub>1</sub> subunits (Schofield et al. (1987) Nature 328:221-227); the bovine α<sub>2</sub> and α<sub>3</sub> subunits (Levitan et al. (1988) Nature 335:76-79); the γ-subunit (Pritchett et al. (1989) Nature 338:582-585); the β<sub>2</sub> and β<sub>3</sub> subunits (Ymer et al. (1989) EMBO J. 8:1665-1670); the δ subunit (Shivers, B. D. (1989) Neuron 3:327-337); and the like); glutamate receptors (e.g., receptor isolated from rat brain (Hollmann et al. (1989) Nature 342:643-648); and the like); adrenergic receptors (e.g., human β1 (Frielle et al. (1987) PNAS 84:7920-7924); human α2 (Kobilka et al. (1987) Science 238:650-656); hamster β2 (Dixon et al. (1986) Nature 321:75-79); and the like); dopamine receptors (e.g., human D2 (Stormann et al. (1990) Molec. Pharm.37:1-6); rat (Bunzow et al. (1988) Nature 336:783-787); and the like); NGF receptors (e.g., human NGF receptors (Johnson et al. (1986) Cell 47:545-554); and the like); serotonin receptors (e.g., human 5HT1a (Kobilka et al. (1987) Nature 329:75-79); rat 5HT2 (Julius et al. (1990) PNAS 87:928-932); rat 5HT1c (Julius et al. (1988) Science 241:558-564); and the like).</p>
    <p>Exemplary ion channels, in addition to those described above, include calcium ion channels (e.g., human neuronal α<sub>2</sub> subunit (see WO89/09834); rabbit skeletal muscle α1 subunit (Tanabe et al. (1987) Nature 328:313-318); rabbit skeletal muscle α2 subunit (Ellis et al. (1988) Science 241:1661-1664); rabbit skeletal muscle β subunit (Ruth et al. (1989) Science 245:1115-1118); rabbit skeletal muscle γ subunit (Jay et al. (1990) Science 248:490-492); and the like); potassium ion channels (e.g., rat brain (BK2) (McKinnon, D. (1989) J. Biol. Chem. 264:8230-8236); mouse brain (BK1) (Tempel et al. (1988) Nature 332:837-839); and the like); sodium ion channels (e.g., rat brain I and II (Noda et al. (1986) Nature 320:188-192); rat brain III (Kayano et al. (1988) FEBS Lett. 228:187-194); and the like).</p>
    <p>Exemplary transcriptional control elements, in addition to those described above, include VIP gene promoter (cAMP responsive; Fink et al. (1988), Proc. Natl. Acad. Sci. 85:6662-6666); the somatostatin gene promoter (cAMP responsive; Montminy et al. (1986), Proc. Natl. Acad. Sci. 83:6682-6686); the proenkephalin promoter (responsive to cAMP, nicotinic agonists, and phorbol esters; Comb et al. (1986), Nature 323:353-356); the phosphoenolpyruvate carboxykinase gene promoter (cAMP responsive; Short et al. (1986), J. Biol. Chem. 261:9721-9726); the NGFI-A gene promoter (responsive to NGF, cAMP, and serum; Changelian et al. (1989). Proc. Natl. Acad. Sci. 86:377-381); and the like.</p>
    <p>Exemplary reporter genes, in addition to those described above, include CAT (Alton and Vapnek (1979), Nature 282: 864-869); firefly luciferase (deWet et al. (1987), Mol. Cell. Biol. 7: 725-737); bacterial luciferase (Engebrecht and Silverman (1984), PNAS 1: 4154-4158; Baldwin et al. (1984), Biochemistry 23: 3663-3667); alkaline phosphatase (Toh et al. (1989), Eur. J. Biochem. 182: 231-238); and the like.</p>
    <p>The invention will now be described in greater detail by reference to the following non-limiting examples.</p>
    <heading>EXAMPLES</heading> <heading>Example I. DEVELOPMENT OF HM1-EXPRESSING, c-fos-CAT-CONTAINING MAMMALIAN CELLS</heading> <p>Stable cell lines were developed to provide a transcription-based assay system by cotransfecting Ltk cells (mouse fibroblast thymidine kinase deficient) with a plasmid comprised of the HM1-encoding sequence, a selection plasmid comprised of either the wild-type or crippled TK gene, and a reporter gene expression construct.</p>
    <p>A. Host Cells</p>
    <p>HEK 293 available from ATCC (accession #CRL 1573)</p>
    <p>LKt cells are available from ATCC (accession #CCL1.3).</p>
    <p>COS7 available from ATCC (accession #CRL 1651)</p>
    <p>DG44 (see L. Chasin (1986) Cell. Molec. Genet. 12: 555)</p>
    <p>B. HM1 expression plasmid</p>
    <p>The sequence of the HM1-encoding DNA fragment is described in Allard et al. (1987), Nucl. Acids Res. 15:10604. It can be obtained as described by Allard et al., or it can be isolated by screening a partial human genomic DNA library, comprised of 2.5-4.5 kb-sized EcoRI fragments in the λgtll vector, with an oligonucleotide homologous to nucleotides 250-279 of the HM1 sequence. Nucleotides 250-279 have the following sequence: ACG TAC CTG CTC ATG GGC CAC TGG GCT CTG. Screening conditions employed were as follows:</p>
    <p>hybridization: 20% deionized formamide, 5 X Denhardt's, 6 X SSPE, 0.2% SDS, 200 μg/ml sonicated herring sperm DNA, 42° C.</p>
    <p>wash: 0.2 X SSPE, 0.2% SDS, 50° C.</p>
    <p>A positive clone was identified and confirmed to encode the HM1 receptor by DNA sequencing. The EcoRI insert of that clone was isolated and inserted into the EcoRI site of pIBI24 (International Biotechnologies, Inc., New Haven, Conn.), yielding clone pIBI24/HM1.</p>
    <p>The HM1-encoding fragment of pIBI24/HM1 was modified for insertion into the SV40 promoter-based plasmid pSV2dhfr (see Subramani et al. (1981) Mol. Cell. Biol. 1: 854-864). Fifty nanograms of the 1.97 kb BamHI fragment from pIBI24/HM1 were ligated with 50 ng of BamHI-digested M13mp18. The ligation was transformed into E. coli strain JM103, and Amp<sup>R</sup> colonies were selected. Correct plasmid was identified by the presence of a 1.45 KpnI digestion fragment. Template was prepared from this plasmid to introduce an EcoRI site immediately before the initiation codon of the human HM1 coding region. This was accomplished by standard mutagenesis using an oligonucleotide of the following sequence: 5' CCC CAG CCC CAC CTT GAA TTC ATG AAC ACT TCA GCC 3' The mutagenesis products were transformed into JM103 and screened on plaque lifts with an oligonucleotide of the following sequence: 5' CAC CTT GAA TTC ATG AAC 3' Four of the positive clones were subjected to dideoxy sequencing and all were found to have the correct sequence. One of these, mHM1AChR103, was subjected to further mutagenesis to introduce an EcoRI site immediately following the human HM1 terminating codon. The mutagenizing oligonucleotide was of the following sequence: 5' CTC CCG CCA ATG CTG AGA ATT CTA TCT CCT GCA TCC C 3' Mutagenesis products were transformed into JM103 and screened on plaque lifts with an oligonucleotide of the following sequence: 5' CTG AGA ATT CTA TCT CC 3' Four of the positive clones were sequenced, and all had the correct sequence. One of these, M3HM1AR04, was digested with EcoRI and the 1.4 kb fragment representing the human M1 coding region was gel purified and eluted using DE-81 paper. Sixty nanograms of the 1.4 kb fragment were ligated with 20 ng of EcoRI-digested pUC19. Correct clones were identified by the presence of a 1.2 kb KpnI fragment. One of these was chosen and designated pHM1RO2. The 1.4 kb fragment was removed from pHM1RO2 and inserted (38.5 ng) into 50 ng of EcoRI-digested pSV2dhfr. The ligation was transformed into DH5α (Sombrook et al., Molecular Cloning, 2nd ed., CSH Lab, 1989, p. 10) cells and AmpR colonies were selected. Correct plasmid demonstrated bands of 1.4 and 5.0 kb upon digestion with EcoRI and 250, 1150, and 5000 bp bands upon digestion with PvuII. The final HM1 expression vector was called HM1pSV2dHFR.</p>
    <p>C. TK<sup>+</sup> Selection Plasmids</p>
    <p>The TK<sup>+</sup> plasmid cotransfected into Ltk<sup>-</sup> cells along with the muscarinic receptor-expressing plasmids was either pThx59 [Zipser, et al. (1981), Proc. Natl. Acad. Sci. 78:6276-6280] which encodes the wildtype TK gene, or pThx24 (ibid.) which encodes a crippled TK gene.</p>
    <p>The starting material for construction of the TK<sup>+</sup> selection plasmids was a hybrid plasmid containing the 3500 base pair BamHI DNA fragment of HSV-1 that encodes TK inserted into pBR322. The hybrid plasmid contains the TK promoter adjacent to the unique HindIII site of pBR322. Monomers of hybrid plasmid were linearized by partial digestion with HaeIII, linears were purified on agarose gels and portions of 5' sequence removed before the cap site of the TK gene. The linears were religated. Plasmids that, upon transfection into mammalian cells, expressed low levels of thymidine kinase were among the religated plasmids.</p>
    <p>D. Reporter Gene Expression Plasmid</p>
    <p>A reporter gene expression plasmid comprised of the CAT gene regulated by the c-fos promoter, plasmid pFC4 [(Deschamps et al., Science 230:1174-1177 (1985)], also was cotransfected into the cells.</p>
    <p>Briefly, a 1.4 Kb NaeI (FC2) fragment from the human c-fos gene upstream region (van Straaten et al. (1983) Proc. Natl. Acad. Sci. USA 80:3183), which contains the c-fos promoter and upstream sequence was inserted using HindIII linkers into the vector, pSV2CAT (Gorman et al. (1982) Mol. Cell Biol. 2:1044) in place of the AceI-HindIII fragment in pSV2CAT. A series of plasmids were generated using by deleting portions of the upstream sequence from FC2. Deletion of the SstII to SstII fragment in FC2 yielded FC4. After the deleted fragments that correspond to the residual flanking sequences and fos promoter were digested with Hind III and separated by gel electrophoresis, they were cloned into the SmaI-HindIII digested DNA in place of the original 1.3 Kb fragment in pFC2 to produce pFC4.</p>
    <p>In the constructs described below, unless indicated otherwise, the c-fos promoter region is obtained as the 400 bp fragment from pFC4, which includes a 500 bp insert from the c-fos promoter. The 5'- 100 base pair portion is derived from a noncontiguous distal upstream region.</p>
    <p>E. Transfection and TK<sup>+</sup> Selection</p>
    <p>The CaPO<sub>4</sub> transfection procedure was used in the development of stable HM1-expressing cell lines. The protocol followed was that of Wigler, et al. (1979), Proc. Natl. Acad. Sci. 76:1373-1376.</p>
    <p>Briefly, Ltk<sup>-</sup> cells were grown in nonselective medium [D+10 (Dulbecco's modified Eagle's medium+10% calf serum), 100 U/ml penicillin, and 100 μg/ml streptomycin] in a 10 cm-sized dish, to 20% confluence. The three circular vector DNAs were co-precipitated with CaPO<sub>4</sub> and added to the cell monolayer. The vector concentrations were as follows: ##STR1## The transfected cells were allowed to grow for two days in nonselective medium. After two days, the cells were passed and non-selective media was replaced with HAT medium (D+10+15 μg/ml hypoxanthine+1 μg/ml aminopterin+5 μg/ml thymidine), and the cells were left to grow for 10-15 days, during which time the cells were "fed" fresh selective (HAT) medium every 3-4 days. After 10-15 days, colonies or clones appeared which indicated acceptance and expression of at least the plasmid carrying the TK gene. Colonies were transferred into separate wells of a 24-well dish and grown in selective medium for seven days, at which time individual clones were passed into 6-well dishes and grown for another seven days in selective medium. To provide cells for freezing and subsequent molecular and functional receptor analyses, the individual clones in the 6-well dishes were passed to 100 ml dishes.</p>
    <heading>Example II. DEVELOPMENT OF CONTROL CELL LINES</heading> <p>Two series of control cell lines were developed according to the methods in Example I.</p>
    <p>The first series was developed by cotransfecting Ltk<sup>-</sup> cells with HM1 and TK<sup>+</sup> DNAs as described in Example 1. These cell lines, examples of which were named LM159-10 and LM124-3, served as positive controls to show that activation of the expressed HM1 receptor led to an increase in endogenous c-fos RNA. These cell lines also served as negative controls to show that CAT mRNA or enzyme activity was not detected in the absence of the pFC4 reporter construct.</p>
    <p>The second series of control cell lines was developed by cotransfecting Ltk<sup>-</sup> cells with pFC4 and TK<sup>+</sup> DNAs. These cell lines, examples of which were called LFC4-3, LFC4-5, LFC4-7, LFC4-8, and LFC4-10, served as positive controls to show CAT mRNA and enzyme activity in response to compounds which activate the c-fos promoter. These cell lines also served as negative controls to show that CAT mRNA and enzyme activity were not altered when these cells were contacted with HM1 agonists or antagonists (because they do not express the HM1 receptor).</p>
    <p>An additional negative control cell line was untransfected Ltk<sup>-</sup> cells, whereas a positive control cell line was PC12 cells (ATCC CRL1721).</p>
    <heading>Example III. CHARACTERIZATION OF CELL LINES</heading> <p>The cell lines employed in the practice of the present invention were then characterized by one or more of the following methods.</p>
    <p>A. Analysis of HM1-, c-fos, and/or CAT-encoding RNA</p>
    <p>The cell lines first were analyzed for expression of HM1-encoding RNA. Total RNA was isolated from 1×10<sup>7</sup> cells and 10-15 μg of each RNA were separated on a 1% agarose-formaldehyde gel, followed by transfer onto nitrocellulose. The northern blot was separately probed with one or more of the following probes:</p>
    <p>HM1--random-primed 1.2 Kb EcoRI fragment from plasmid pSV2HM1</p>
    <p>CAT--random-primed 788 bp TaqI fragment from plasmid pCaMVCN</p>
    <p>c-fos--random-primed 1.1 Kb PstI fragment from plasmid pvfos</p>
    <p>The hybridization and wash conditions were as follows: hybridization in 0.2X SSPE at room temperature wash at 65° C.</p>
    <p>The expected sizes of the hybridizing bands are as follows:</p>
    <p>HM1- .sup.˜ 3 kb</p>
    <p>CAT - .sup.˜ 2 kb</p>
    <p>c-fos -2.2 kb</p>
    <heading>B. M1 receptor binding assay</heading> <p>PC12 cells [Michel et al., Br. J. Pharmacol. 97:914-920 (1989)], and SH-SY5Y cells [Lambert et al., Eur. J. Pharmacol. 165:71-77 (1989); Serra et al., J. Neurochem. 50:1513-1521 (1988)] serve as a positive control for agonist and antagonist binding to HM1-expressing cells. Approximately 1×10<sup>6</sup> cells (control or invented) were incubated with 1.4 nM of the antagonist [<sup>3</sup> H]-N-methyl-scopolamine (NMS) for 1 hr at 37° C., in the absence or presence of various concentrations of agonists, i.e., atropine, pirenzepine, carbamylcholine, scopolamine. Unbound labeled ligand was separated from cell-bound label by filtration of the assay mixture through Whatman GF/C filters, which had been pretreated with polyethyleneimine. The filters were washed with 4 ml of ice-cold assay buffer (144 mM NaCl, 4.7 mM KCl, 1.7 mM KH<sub>2</sub> PO<sub>4</sub>, 2.5 mM CaCl<sub>2</sub>.2H<sub>2</sub> O, 1.1 mM MgCl<sub>2</sub>, 10 mM glucose, 10 mM Tris/HCl), dried and analyzed in a scintillation counter to determine the amount of bound <sup>3</sup> H-NMS. Counts bound in the presence of atropine were subtracted from counts bound in the absence of atropine to determine extent of specific binding.</p>
    <p>The results of these competitive binding experiments yielded IC<sub>50</sub> values for displacement of specifically bound <sup>3</sup> H-NMS as follows:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________              carbamyl-Cell line    pirenzepine              choline   atropine                               scopolamine______________________________________PC12     900 nM    200    μM                          7.0 nM 5 nMSH-SY5Y  300 nM    17     μM                          4.0 nM 4 nMLM159-10 200 nM    1      mM   4.5 nM 2 nMLM124-3  200 nM    &gt;1     mM   1.5 nM 2 nMLM1FC4-8  40 nM    100    μM                          5.0 nM 2 nMLM1FC4-15     60 nM    170    μM                          4.0 nM 3 nM______________________________________</pre>
    
    <p>These results are in close agreement with those reported by Michael et al., Supra, for the muscarinic pharmacology of PC12 cells. Further, cell lines developed by transfection with HM1 or HM1 and c-fos-CAT expression vectors express HM1 receptors which exhibit expected pharmacological properties.</p>
    <p>C. PI hydrolysis assay</p>
    <p>The activation of the M1 muscarinic receptor by an agonist results in activation of the phosphotidyl inositol (PI) hydrolysis cascade. The functional assay involves labeling of cells with <sup>3</sup> H-myo-inositol for 48 hrs. The cells then are treated with the muscarinic agonist, carbamylcholine (CCh), in the presence and absence of the muscarinic antagonist, atropine, for one hour before they are lysed and extracted in chloroform-methanol-water. Finally, the inositol phosphates are separated by ion exchange chromatography and quantitated by scintillation counting.</p>
    <p>The protocol followed in this work is a modification of that reported in Sevva et al. (1986), Biochem. Biophys. Res. Comm. 140:160-166 and Peralta et al. (1988), Nature 334:434-437. Briefly, control cells (SHSY5Y or PC12 cells) and experimental cells were plated on 12-well plates (Costar) at a density of 5×10<sup>5</sup> cells/well and labeled with <sup>3</sup> H-myo-inositol (3 μCi/well) for 65-70 hrs. The medium was decanted and the wells washed with 1 ml of 2X PI assay buffer (10 mM Hepes, 0.5 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM LiCl in 500 ml DMEM). The cells were then incubated with or without various concentrations of agonists, or incubated with agonist with or without various concentrations of antagonists, for 60 min at 37° C. The cells were then lysed and the suspension extracted with 3 ml of CHCl<sub>3</sub> /MeOH (1:1). After centrifugation (3200 rpm for 5 min), the upper aqueous phase was removed and diluted with 2 ml H<sub>2</sub> O and centrifuged again. The supernatants were then loaded on 1 ml Dowex 1X8 AG resin previously equilibrated with 5 mM myo-inositol. The columns were then washed with 9 ml of 5 mM myo-inositol followed by 8 ml of 60 mM sodium formate, 5 mM sodium borate. All of the inositol phosphates (IP1, IP2, IP3) were eluted together with 6 ml of 0.1M formic acid, 1M ammonium formate. 3 ml of the eluates were removed and counted with 20 ml scintillation fluid for analysis. Fold stimulation was determined by the cps agonist/cpm buffer control. EC<sub>50</sub> and IC<sub>50</sub> were determined by subtracting the buffer controls and plotting the agonist or antagonist with the percent maximum response (agonist only).</p>
    <p>As in the receptor binding assays, SH-SY5Y (Serra et al., Supra) and PC12 [Horowitz, J., J. Neurochem. 53:197-204 (1989)] cells serve as positive control systems for activation of the PI hydrolysis pathway by muscarinic agonists and inhibition of the stimulation by muscarinic antagonists. In the positive control cell line SH-SY5Y, treatment with 1 mM CCh resulted in approximately 50-fold stimulation of inositol phosphate accumulation, which was blocked by 100 nM atropine. In the PC12 cells, treatment with 1 mM CCh resulted in 27-fold activation. The negative control cell line, 59-0 cells, did not respond to CCh treatment while the cells transfected with the M1 cDNA displayed varying levels of CCh stimulation. The stimulation observed with 1 mM CCh is summarized below for the positive control and transfected cell lines.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Cell lineFold Stimulation           ED<sub>50</sub>, μM______________________________________PC12          27            7SH-SY5Y       48           18LM1/10         9           90LM1/24-3      28           48LM1/FC4-8     30           61LM1/FC4-15     4           48______________________________________</pre>
    
    <p>The pharmacological properties of the transfected cell lines, LM1/24-3, LM1/10, LM1/FC4-8, and LM1/FC4-15 cells, as well the SH-SY5Y and PC12 cells were characterized by studying the dose-dependent inhibition of CCh-stimulated inositol phosphate accumulation by the muscarinic antagonists atropine, pirenzepine, and scopolamine. The IC<sub>50</sub> values obtained for the antagonists are tabulated in below:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Cell line Pirenzepine                Atropine    Scopolamine______________________________________PC12      900     μM  &gt;100   nM   NDSHSY5Y    3.3     μM  47     nM   36 nMLM159-10  0.5     μM  13     nM   31 nMLM124-3   0.2     μM  15     nM   15 nMLM1FC4-8  0.3     μM  21     nM   18 nMLM1FC4-15 ND             10     nM   ND______________________________________ ND = not determined</pre>
    
    <heading>D. Transcription-based assay</heading> <p>Control and invention cells to be employed in the invention transcription-based assay were treated as follows: cells were grown to 70-80% confluence and then grown in 0.5% serum media for two days prior to assay. This serum starvation step decreases background levels of c-fos promoter transcription. For each cell type to be assayed, groups of three plates of cells were similarly treated. The various treatments included treatment with 100-500 μM carbachol for 15-45 min, treatment with 20% serum for 15-45 min, no treatment, but were swirled as were the others, and treatment with 10 μM atropine for 5 min prior to treatment with carbachol. One plate in each group was incubated for 30-60 min at 37° C., and then used to isolate total RNA for northern analysis (see Example III.A.). The other two plates were incubated for 5 hr at 37° C. and then subjected to assay for CAT activity.</p>
    <p>1. CAT assay</p>
    <p>The CAT activity assay was conducted as follows: Protein lysates were prepared by washing the plates with phosphate-buffered saline (PBS) and then lysing cells on the plate in 500 μl 10.25M Tris.HCl pH7.8, 1% Triton X100. The lysate is transferred to an eppendorf tube and then incubated at 65° C. for 10 min. A 5 min spin in a microfuge at 4° C. was followed by transfer of the lysate to fresh tubes and freezing at -20° C. until time to assay.</p>
    <p>At time of assay, BioRad protein assays were done in duplicate. 150 μl of cell lysate was used in the CAT assay. 90 μl of dH<sub>2</sub> O, 0.5 μl 500 mM chloramphenicol, and 10 μl <sup>14</sup> C-acetyl CoA or <sup>3</sup> H-acetyl CoA were added to initiate the reaction, which was incubated for 1-4 hr at 37° C. The reaction was stopped on ice, and 300 μl cold ethyl acetate was added. The tubes were vortexed, spun in a microfuge for 1 min, and 200 μl of the organic phase was transferred to a glass scintillation vial. The 300 μl ethyl acetate extraction was repeated and the organic extracts were combined with 5 ml Econofluor scintillation counting solution. Radioactivity was determined in a scintillation counter.</p>
    <p>2. Northern analysis</p>
    <p>The RNA was probed for the presence of c-fos and CAT RNA as described in Example III.A.</p>
    <p>3. Data analysis</p>
    <p>Cell lines which had been transfected with plasmids containing the HM1 gene, e-g., LM159-10 and LM124-3, were analyzed for expression of endogenous c-fos RNA after treatment with the cholinergic agonist carbachol or carbachol and atropine, a muscarinic antagonist. If functional HM1 receptors are present on the surface of the cells, the carbachol should interact with the receptor, resulting in alteration of an intracellular condition to which the endogenous c-fos transcriptional control element is sensitive. The altered intracellular condition should activate the c-fos promoter and the c-fos gene should be transcribed at a higher level. The cascade should be detectable at the RNA level, by an induction of endogenous c-fos RNA. Furthermore, the M1 agonist-mediated induction of c-fos, should be blocked by M1 antagonists. All these results were achieved in cell lines LM159-10 and LM124-3, indicating that they do express HM1 receptors which are associated with a functional c-fos induction pathway.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________c-fos mRNA                          100 μMcell line            100 μM carbachol +atropine   no treatment carbachol 10 μM______________________________________LM159-10   -            +++       +LM124-3 -            +++       +LtK<sup>-</sup>   -            -         -______________________________________</pre>
    
    <p>In cells transfected with the HM1 expression vector plus the c-fos-CAT marker plasmid, e.g., LM1FC4-8 and LM1FC4-15, cells expressing functional HM1 receptors will likewise show an increase in c-fos mRNA upon interaction with an HM1 agonist. However, these cells should also demonstrate an increase in CAT-specific RNA and enzyme activity by nature of activation of the c-fos-CAT expression construct. All these results were achieved in cell line LM1FC4-15 upon treatment with an HM1 agonist (carbachol) and a general c-fos inducer (20% serum).</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________                 100 μMCell line    no treatment carbachol 20% serum______________________________________LM1FC4-8c-fos RNA    -            -         +CAT RNA  +            +         +CAT activity    +            +         +LM1FC4-15c-fos RNA    -            ++        ++CAT RNA  +            ++        ++CAT activity    +            ++        ++LFC4-7c-fos RNA    -            -         +CAT RNA  +            +         ++CAT activity    +            +         ++______________________________________</pre>
    
    <p>The invention has been described in detail with reference to certain particular embodiments thereof, but it will be understood that variations and modifications can be effected with the spirit and scope of the invention.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4859609">US4859609</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 30, 1986</td><td class="patent-data-table-td patent-date-value">Aug 22, 1989</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Binding ligand to polypeptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4981784">US4981784</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 30, 1988</td><td class="patent-data-table-td patent-date-value">Jan 1, 1991</td><td class="patent-data-table-td ">The Salk Institute For Biological Studies</td><td class="patent-data-table-td ">Retinoic acid receptor method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5071773">US5071773</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 20, 1987</td><td class="patent-data-table-td patent-date-value">Dec 10, 1991</td><td class="patent-data-table-td ">The Salk Institute For Biological Studies</td><td class="patent-data-table-td ">Hormone receptor-related bioassays</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5091518">US5091518</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 16, 1989</td><td class="patent-data-table-td patent-date-value">Feb 25, 1992</td><td class="patent-data-table-td ">The Salk Institute For Biological Studies</td><td class="patent-data-table-td ">Beta retinoic acid response elements compositions and assays</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Allard, et al., "<a href='http://scholar.google.com/scholar?q="Sequence+of+the+gene+encoding+the+human+M1+muscarinic+acetylcholine+receptor%2C"'>Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor,</a>" Nucl. Acids. Res., 15:10604 (1987).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Allard, et al., Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor, Nucl. Acids. Res., 15:10604 (1987).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Alton and Vapnek, "<a href='http://scholar.google.com/scholar?q="Nucleotide+sequence+analysis+of+the+chloramphenicol+resistance+transposon+tn9%2C"'>Nucleotide sequence analysis of the chloramphenicol resistance transposon tn9,</a>" Nature, 282:864-869 (1979).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Alton and Vapnek, Nucleotide sequence analysis of the chloramphenicol resistance transposon tn9, Nature, 282:864 869 (1979).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Baldwin, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+of+the+luciferase+structural+genes+from+vibrio+harveyi+and+expression+of+bioluminescence+in+escherichia+coli%2C"'>Cloning of the luciferase structural genes from vibrio harveyi and expression of bioluminescence in escherichia coli,</a>" Biochemistry, 23:3663-3667 (1984).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Baldwin, et al., Cloning of the luciferase structural genes from vibrio harveyi and expression of bioluminescence in escherichia coli, Biochemistry, 23:3663 3667 (1984).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bonner, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+and+expression+of+the+human+and+rat+m5+muscarinic+acetylcholine+receptor+genes%2C"'>Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes,</a>" Neuron, 1:403-410 (1988).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Bonner, et al., Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes, Neuron, 1:403 410 (1988).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Boulter, et al., "<a href='http://scholar.google.com/scholar?q="Isolation+of+a+cDNA+clone+coding+for+a+possible+neural+nicotinic+acetylcholine+receptor+%CE%B1-subunit%2C"'>Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor α-subunit,</a>" Nature, 319:368-374 (1986).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Boulter, et al., "<a href='http://scholar.google.com/scholar?q="%CE%B13%2C+%CE%B15%2C+and+%CE%B24%3A+Three+members+of+the+rat+neuronal+nicotinic+acetylcholine+receptor-related+gene+family+form+a+gene+cluster%2C"'>α3, α5, and β4: Three members of the rat neuronal nicotinic acetylcholine receptor-related gene family form a gene cluster,</a>" J. Biol. Chem., 265:4472-4482 (1990).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Boulter, et al., 3, 5, and 4: Three members of the rat neuronal nicotinic acetylcholine receptor related gene family form a gene cluster, J. Biol. Chem., 265:4472 4482 (1990).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Boulter, et al., Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor subunit, Nature, 319:368 374 (1986).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bunzow, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+and+expression+of+a+rat+D2+dopamine+receptor+cDNA%2C"'>Cloning and expression of a rat D2 dopamine receptor cDNA,</a>" Nature, 336:783-787 (1988).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Bunzow, et al., Cloning and expression of a rat D 2 dopamine receptor cDNA, Nature, 336:783 787 (1988).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Changelian, et al., "<a href='http://scholar.google.com/scholar?q="Structure+of+the+NGFI-A+gene+and+detection+of+upstream+sequences+responsible+for+its+transcriptional+induction+by+nerve+growth+factor%2C"'>Structure of the NGFI-A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor,</a>" Proc. Natl. Acad. Sci., 86:377-381 (1989).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Changelian, et al., Structure of the NGFI A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor, Proc. Natl. Acad. Sci., 86:377 381 (1989).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Collins et al., Proc. Natl. Acad. Sci. USA, vol. 86., (Jul. 1989), pp.  484857.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Collins et al., Proc. Natl. Acad. Sci. USA, vol. 86., (Jul. 1989), pp. 4853 4857.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Comb, et al., "<a href='http://scholar.google.com/scholar?q="A+cyclic+AMP-+and+phorbol+ester-inducible+DNA+element%2C"'>A cyclic AMP- and phorbol ester-inducible DNA element,</a>" Nature, 323:353-356 (1986).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Comb, et al., A cyclic AMP and phorbol ester inducible DNA element, Nature, 323:353 356 (1986).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Deneris, et al., "<a href='http://scholar.google.com/scholar?q="Primary+structure+and+expression+of+%CE%B22%3A+A+novel+subunit+of+neuronal+nicotinic+acetylcholine+receptors%2C"'>Primary structure and expression of β2: A novel subunit of neuronal nicotinic acetylcholine receptors,</a>" Neuron, 1:45-54 (1988).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Deneris, et al., "<a href='http://scholar.google.com/scholar?q="%CE%B23+%3A+A+new+member+of+nicotinic+acetylcholine+receptor+gene+family+is+expressed+in+brain%2C"'>β3 : A new member of nicotinic acetylcholine receptor gene family is expressed in brain,</a>" J. Biol. Chem., 264:6268-6272 (1989).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Deneris, et al., 3 : A new member of nicotinic acetylcholine receptor gene family is expressed in brain, J. Biol. Chem., 264:6268 6272 (1989).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Deneris, et al., Primary structure and expression of 2: A novel subunit of neuronal nicotinic acetylcholine receptors, Neuron, 1:45 54 (1988).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Deschamps, et al., "<a href='http://scholar.google.com/scholar?q="Identification+of+a+transcriptional+enhancer+element+upstream+from+the+proto-oncogen+fos%2C"'>Identification of a transcriptional enhancer element upstream from the proto-oncogen fos,</a>" Science, 230:1174-1177 (1985).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Deschamps, et al., Identification of a transcriptional enhancer element upstream from the proto oncogen fos, Science, 230:1174 1177 (1985).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">deWet, et al., "<a href='http://scholar.google.com/scholar?q="Firefly+luciferase+gene%3A+structure+and+expression+in+mammalian+cells%2C"'>Firefly luciferase gene: structure and expression in mammalian cells,</a>" Mol. Cell. Biol. 7:725-737 (1987).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">deWet, et al., Firefly luciferase gene: structure and expression in mammalian cells, Mol. Cell. Biol. 7:725 737 (1987).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dixon, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+of+the+gene+and+cDNA+for+mammalian+%CE%B2-adrenergic+receptor+and+homology+with+rhodopsin%2C"'>Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin,</a>" Nature, 321:75-79 (1986).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Dixon, et al., Cloning of the gene and cDNA for mammalian adrenergic receptor and homology with rhodopsin, Nature, 321:75 79 (1986).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Duvoisin, et al., "<a href='http://scholar.google.com/scholar?q="The+functional+diversity+of+the+neuronal+nicotinic+acetylcholine+receptors+is+increased+by+a+novel+subunit%3A+%CE%B24%2C"'>The functional diversity of the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: β4,</a>" Neuron, 3:487-496 (1989).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Duvoisin, et al., The functional diversity of the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: 4, Neuron, 3:487 496 (1989).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ellis, et al., "<a href='http://scholar.google.com/scholar?q="Sequence+and+expression+of+mRNAS+encoding+the+%CE%B11+and+%CE%B12+subunits+of+a+DHP-sensitive+calcium+channel%2C"'>Sequence and expression of mRNAS encoding the α1 and α2 subunits of a DHP-sensitive calcium channel,</a>" Science, 241:1661-1664 (1988).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ellis, et al., Sequence and expression of mRNAS encoding the 1 and 2 subunits of a DHP sensitive calcium channel, Science, 241:1661 1664 (1988).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Engebrecht and Silverman, "<a href='http://scholar.google.com/scholar?q="Identification+of+genes+and+gene+products+necessary+for+bacterial+bioluminescence%2C"'>Identification of genes and gene products necessary for bacterial bioluminescence,</a>" PNAS, 1:4154-4158 (1984).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Engebrecht and Silverman, Identification of genes and gene products necessary for bacterial bioluminescence, PNAS, 1:4154 4158 (1984).</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fink, et al., "<a href='http://scholar.google.com/scholar?q="The+CGTCA+sequence+motif+is+essential+for+biological+activity+of+the+vasoactive+intestinal+peptide+gene+cAMP-regulated+enhancer%2C"'>The CGTCA sequence motif is essential for biological activity of the vasoactive intestinal peptide gene cAMP-regulated enhancer,</a>" Proc. Natl. Acad. Sci., 85:6662-6666 (1988).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Fink, et al., The CGTCA sequence motif is essential for biological activity of the vasoactive intestinal peptide gene cAMP regulated enhancer, Proc. Natl. Acad. Sci., 85:6662 6666 (1988).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Frielle, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+of+the+cDNA+for+the+human+%CE%B21+-adrenergic+receptor%2C"'>Cloning of the cDNA for the human β1 -adrenergic receptor,</a>" PNAS, 84:7920-7924 (1987).</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Frielle, et al., Cloning of the cDNA for the human 1 adrenergic receptor, PNAS, 84:7920 7924 (1987).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goldman, et al., "<a href='http://scholar.google.com/scholar?q="Members+of+a+nicotinic+acetylcholine+receptor+gene+family+are+expressed+in+different+regions+of+the+mammalian+central+nervous+system%2C"'>Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system,</a>" Cell, 48:965-973 (1987).</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Goldman, et al., Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system, Cell, 48:965 973 (1987).</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hollmann, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+by+functional+expression+of+a+member+of+the+glutamate+receptor+family%2C"'>Cloning by functional expression of a member of the glutamate receptor family,</a>" Nature, 342:643-648 (1989).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hollmann, et al., Cloning by functional expression of a member of the glutamate receptor family, Nature, 342:643 648 (1989).</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Horowitz, et al., "<a href='http://scholar.google.com/scholar?q="Muscarinic+receptor+stimulation+increases+inositol-phospholipid+metabolism+and+inhibits+cyclic+AMP+accumulation+in+PC12+cells%2C"'>Muscarinic receptor stimulation increases inositol-phospholipid metabolism and inhibits cyclic AMP accumulation in PC12 cells,</a>" J. Neurochem., 53:197-204 (1989).</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Horowitz, et al., Muscarinic receptor stimulation increases inositol phospholipid metabolism and inhibits cyclic AMP accumulation in PC12 cells, J. Neurochem., 53:197 204 (1989).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jay, et al., "<a href='http://scholar.google.com/scholar?q="Primary+structure+of+the+%CE%B3+subunit+of+the+DHP-sensitive+calcium+channel+from+skeletal+muscle%2C"'>Primary structure of the γ subunit of the DHP-sensitive calcium channel from skeletal muscle,</a>" Science, 248:490-492 (1990).</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Jay, et al., Primary structure of the subunit of the DHP sensitive calcium channel from skeletal muscle, Science, 248:490 492 (1990).</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Johnson, et al., "<a href='http://scholar.google.com/scholar?q="Expression+and+structure+of+the+human+NGF+receptor%2C"'>Expression and structure of the human NGF receptor,</a>" Cell, 47:545-554 (1986).</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Johnson, et al., Expression and structure of the human NGF receptor, Cell, 47:545 554 (1986).</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Julius, et al., "<a href='http://scholar.google.com/scholar?q="Molecular+characterization+of+a+functional+cDNA+encoding+the+serotonin+1c+receptor%2C"'>Molecular characterization of a functional cDNA encoding the serotonin 1c receptor,</a>" Science, 241:558-564 (1988).</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Julius, et al., "<a href='http://scholar.google.com/scholar?q="The+5HT2+receptor+defines+a+family+of+structurally+distnict+but+functionally+conserved+serotonin+receptors%2C"'>The 5HT2 receptor defines a family of structurally distnict but functionally conserved serotonin receptors,</a>" PNAS, 87:928-932 (1990).</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Julius, et al., Molecular characterization of a functional cDNA encoding the serotonin 1c receptor, Science, 241:558 564 (1988).</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Julius, et al., The 5HT2 receptor defines a family of structurally distnict but functionally conserved serotonin receptors, PNAS, 87:928 932 (1990).</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kayano, et al., "<a href='http://scholar.google.com/scholar?q="Primary+structure+of+rat+brain+sodium+channel+III+deduced+from+the+cDNA+sequence%2C"'>Primary structure of rat brain sodium channel III deduced from the cDNA sequence,</a>" FEBS Lett., 228:187-194 (1988).</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kayano, et al., Primary structure of rat brain sodium channel III deduced from the cDNA sequence, FEBS Lett., 228:187 194 (1988).</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kobilka, et al., "<a href='http://scholar.google.com/scholar?q="An+intronless+gene+encoding+a+potential+member+of+the+fmaily+of+receptors+coupled+to+guanine+nucleotide+regulatory+proteins%2C"'>An intronless gene encoding a potential member of the fmaily of receptors coupled to guanine nucleotide regulatory proteins,</a>" Nature, 329:75-79 (1987).</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kobilka, et al., "<a href='http://scholar.google.com/scholar?q="Cloning%2C+sequencing%2C+and+expression+of+the+gene+coding+for+the+human+platelet+%CE%B12+-adrenergic+receptor%2C"'>Cloning, sequencing, and expression of the gene coding for the human platelet α2 -adrenergic receptor,</a>" Science, 238:650-656 (1987).</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kobilka, et al., An intronless gene encoding a potential member of the fmaily of receptors coupled to guanine nucleotide regulatory proteins, Nature, 329:75 79 (1987).</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kobilka, et al., Cloning, sequencing, and expression of the gene coding for the human platelet 2 adrenergic receptor, Science, 238:650 656 (1987).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lamb, et al., "<a href='http://scholar.google.com/scholar?q="Demonstration+in+living+cells+of+an+intragenic+negative+regulatory+element+within+the+rodent+c-fos+gene%2C"'>Demonstration in living cells of an intragenic negative regulatory element within the rodent c-fos gene,</a>" Cell, 61:485-496 (1990).</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lamb, et al., Demonstration in living cells of an intragenic negative regulatory element within the rodent c fos gene, Cell, 61:485 496 (1990).</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lambert, et al., "<a href='http://scholar.google.com/scholar?q="Muscarinic+receptor+binding+characteristics+of+a+human+neuroblastomas+SK-N-SH+and+its+clones+SH-SY5Y+and+SH-EP1%2C"'>Muscarinic receptor binding characteristics of a human neuroblastomas SK-N-SH and its clones SH-SY5Y and SH-EP1,</a>" Eur. J. Pharmacol., 165:71-77 (1988).</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lambert, et al., Muscarinic receptor binding characteristics of a human neuroblastomas SK N SH and its clones SH SY5Y and SH EP1, Eur. J. Pharmacol., 165:71 77 (1988).</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Levitan, et al., "<a href='http://scholar.google.com/scholar?q="Structural+and+functional+basis+for+GABAA+receptor+heterogeneity%2C"'>Structural and functional basis for GABAA receptor heterogeneity,</a>" Nature, 335:76-79 (1988).</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Levitan, et al., Structural and functional basis for GABA A receptor heterogeneity, Nature, 335:76 79 (1988).</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">McKinnon, D., "<a href='http://scholar.google.com/scholar?q="Isolation+of+a+cDNA+clone+coding+for+a+putative+second+potassium+channel+indicates+the+existence+of+a+gene+family%2C"'>Isolation of a cDNA clone coding for a putative second potassium channel indicates the existence of a gene family,</a>" J. Biol. Chem., 264:8230-8236 (1989).</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">McKinnon, D., Isolation of a cDNA clone coding for a putative second potassium channel indicates the existence of a gene family, J. Biol. Chem., 264:8230 8236 (1989).</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Michel, et al., "<a href='http://scholar.google.com/scholar?q="PC12+phaeochromocytoma+cells+contain+an+atypical+muscarinic+receptor+binding+site%2C"'>PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site,</a>" Br. J. Pharmacol., 97:914-920 (1989).</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Michel, et al., PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site, Br. J. Pharmacol., 97:914 920 (1989).</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Montminy, et al., "<a href='http://scholar.google.com/scholar?q="Identification+of+a+cyclic-AMP-responsive+element+within+the+rat+somatostatin+gene%2C"'>Identification of a cyclic-AMP-responsive element within the rat somatostatin gene,</a>" Proc. Natl. Acad. Sci., 83:6682-6686 (1986).</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Montminy, et al., Identification of a cyclic AMP responsive element within the rat somatostatin gene, Proc. Natl. Acad. Sci., 83:6682 6686 (1986).</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Noda, et al., "<a href='http://scholar.google.com/scholar?q="Existence+of+distinct+sodium+channel+messenger+RNAs+in+rat+brain%2C"'>Existence of distinct sodium channel messenger RNAs in rat brain,</a>" Nature, 320:188-192 (1986).</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Noda, et al., Existence of distinct sodium channel messenger RNAs in rat brain, Nature, 320:188 192 (1986).</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Peralta, et al., "<a href='http://scholar.google.com/scholar?q="Differential+regulation+of+PI+hydrolysis+and+adenylyl+cyclase+by+mascarinic+receptor+subtypes%2C"'>Differential regulation of PI hydrolysis and adenylyl cyclase by mascarinic receptor subtypes,</a>" Nature, 334:434-437 (1988).</td></tr><tr><td class="patent-data-table-td ">76</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Peralta, et al., Differential regulation of PI hydrolysis and adenylyl cyclase by mascarinic receptor subtypes, Nature, 334:434 437 (1988).</td></tr><tr><td class="patent-data-table-td ">77</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pritchett, et al., "<a href='http://scholar.google.com/scholar?q="Importance+of+a+novel+GABAA+receptor+subunit+for+benzodiazepine+pharmacology%2C"'>Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology,</a>" Nature, 338:582-585 (1989).</td></tr><tr><td class="patent-data-table-td ">78</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Pritchett, et al., Importance of a novel GABA A receptor subunit for benzodiazepine pharmacology, Nature, 338:582 585 (1989).</td></tr><tr><td class="patent-data-table-td ">79</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ruth, et al., "<a href='http://scholar.google.com/scholar?q="Primary+structure+of+the+%CE%B2+subunit+of+the+DHP-sensitive+calcium+channel+from+skeletal+muscle%2C"'>Primary structure of the β subunit of the DHP-sensitive calcium channel from skeletal muscle,</a>" Science, 245:1115-1118 (1989).</td></tr><tr><td class="patent-data-table-td ">80</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ruth, et al., Primary structure of the subunit of the DHP sensitive calcium channel from skeletal muscle, Science, 245:1115 1118 (1989).</td></tr><tr><td class="patent-data-table-td ">81</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schofield, et al., "<a href='http://scholar.google.com/scholar?q="Sequence+and+functional+expression+of+the+GABAA+receptor+shows+a+ligand-gated+receptor+super-family%2C"'>Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family,</a>" Nature, 328:221-227 (1987).</td></tr><tr><td class="patent-data-table-td ">82</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Schofield, et al., Sequence and functional expression of the GABA A receptor shows a ligand gated receptor super family, Nature, 328:221 227 (1987).</td></tr><tr><td class="patent-data-table-td ">83</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Serra, et al., "<a href='http://scholar.google.com/scholar?q="Phorbol+esters+alter+muscarinic+receptor+binding+and+inhibit+polyphosphoninositide+breakdown+in+human+neuroblastoma+%28SH-SY5Y%29+cells%2C"'>Phorbol esters alter muscarinic receptor binding and inhibit polyphosphoninositide breakdown in human neuroblastoma (SH-SY5Y) cells,</a>" Biochem. Biophys. Res. Comm., 140:160-166 (1988).</td></tr><tr><td class="patent-data-table-td ">84</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Serra, et al., "<a href='http://scholar.google.com/scholar?q="The+intact+human+neuroblastoma+cell+%28SH-SY5Y%29+exhibits+high-affinity+%5B3+H%5Dpirenzepine+binding+associated+with+hydrolysis+of+phosphatidylinositols%2C"'>The intact human neuroblastoma cell (SH-SY5Y) exhibits high-affinity [3 H]pirenzepine binding associated with hydrolysis of phosphatidylinositols,</a>" J. Neurochem., 50:1513-1521 (1988).</td></tr><tr><td class="patent-data-table-td ">85</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Serra, et al., Phorbol esters alter muscarinic receptor binding and inhibit polyphosphoninositide breakdown in human neuroblastoma (SH SY5Y) cells, Biochem. Biophys. Res. Comm., 140:160 166 (1988).</td></tr><tr><td class="patent-data-table-td ">86</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Serra, et al., The intact human neuroblastoma cell (SH SY5Y) exhibits high affinity 3 H pirenzepine binding associated with hydrolysis of phosphatidylinositols, J. Neurochem., 50:1513 1521 (1988).</td></tr><tr><td class="patent-data-table-td ">87</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sheng, et al., "<a href='http://scholar.google.com/scholar?q="The+regulation+and+function+of+c-fos+and+other+immediate+early+genes+in+the+nervous+system%2C"'>The regulation and function of c-fos and other immediate early genes in the nervous system,</a>" Neuron, 4:477-485 (1990).</td></tr><tr><td class="patent-data-table-td ">88</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sheng, et al., The regulation and function of c fos and other immediate early genes in the nervous system, Neuron, 4:477 485 (1990).</td></tr><tr><td class="patent-data-table-td ">89</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Shivers, B. D., "<a href='http://scholar.google.com/scholar?q="Two+novel+GABAA+receptor+subunits+exist+in+distinct+neuronal+subpopulations%2C"'>Two novel GABAA receptor subunits exist in distinct neuronal subpopulations,</a>" Neuron, 3:327-337 (1989).</td></tr><tr><td class="patent-data-table-td ">90</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Shivers, B. D., Two novel GABA A receptor subunits exist in distinct neuronal subpopulations, Neuron, 3:327 337 (1989).</td></tr><tr><td class="patent-data-table-td ">91</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Short, et al., "<a href='http://scholar.google.com/scholar?q="Characterization+of+the+phosphoenolpyruvate+carboxykinase+%28GTP%29+promoter-regulatory+region%2C"'>Characterization of the phosphoenolpyruvate carboxykinase (GTP) promoter-regulatory region,</a>" J. Biol. Chem., 261:9721-9726 (1986).</td></tr><tr><td class="patent-data-table-td ">92</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Short, et al., Characterization of the phosphoenolpyruvate carboxykinase (GTP) promoter regulatory region, J. Biol. Chem., 261:9721 9726 (1986).</td></tr><tr><td class="patent-data-table-td ">93</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Stormann, et al., "<a href='http://scholar.google.com/scholar?q="Molecular+cloning+and+expression+of+a+dopamine+D2+receptor+from+human+retina%2C"'>Molecular cloning and expression of a dopamine D2 receptor from human retina,</a>" Molec. Pharm. 37:1-6 (1990).</td></tr><tr><td class="patent-data-table-td ">94</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Stormann, et al., Molecular cloning and expression of a dopamine D2 receptor from human retina, Molec. Pharm. 37:1 6 (1990).</td></tr><tr><td class="patent-data-table-td ">95</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Subramani, et al., "<a href='http://scholar.google.com/scholar?q="Expression+of+the+mouse+dihydrofolate+complementary+deoxyribonucleic+reductase+acid+in+simian+virus+40%2C"'>Expression of the mouse dihydrofolate complementary deoxyribonucleic reductase acid in simian virus 40,</a>" Mol. Cell. Biol., 1:854-864 (1981).</td></tr><tr><td class="patent-data-table-td ">96</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Subramani, et al., Expression of the mouse dihydrofolate complementary deoxyribonucleic reductase acid in simian virus 40, Mol. Cell. Biol., 1:854 864 (1981).</td></tr><tr><td class="patent-data-table-td ">97</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tanabe, et al., "<a href='http://scholar.google.com/scholar?q="Primary+structure+of+the+receptor+for+calcium+channel+b+lockers+from+skeletal+muscle%2C"'>Primary structure of the receptor for calcium channel b lockers from skeletal muscle,</a>" Nature, 328:313-318 (1987).</td></tr><tr><td class="patent-data-table-td ">98</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tanabe, et al., Primary structure of the receptor for calcium channel b lockers from skeletal muscle, Nature, 328:313 318 (1987).</td></tr><tr><td class="patent-data-table-td ">99</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tempel, et al., "<a href='http://scholar.google.com/scholar?q="Cloning+of+a+probable+potassium+channel+gene+from+mouse+brain%2C"'>Cloning of a probable potassium channel gene from mouse brain,</a>" Nature, 332:837-839 (1988).</td></tr><tr><td class="patent-data-table-td ">100</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tempel, et al., Cloning of a probable potassium channel gene from mouse brain, Nature, 332:837 839 (1988).</td></tr><tr><td class="patent-data-table-td ">101</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Toh, et al., "<a href='http://scholar.google.com/scholar?q="Isolation+and+characterization+of+a+rat+liver+alkaline+phosphatase+gene%2C"'>Isolation and characterization of a rat liver alkaline phosphatase gene,</a>" Eur. J. Biochem., 182:231-238 (1989).</td></tr><tr><td class="patent-data-table-td ">102</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Toh, et al., Isolation and characterization of a rat liver alkaline phosphatase gene, Eur. J. Biochem., 182:231 238 (1989).</td></tr><tr><td class="patent-data-table-td ">103</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Verma, et al., "<a href='http://scholar.google.com/scholar?q="Proto-Oncogene+fos%3A+Complex+but+versatile+regulation%2C"'>Proto-Oncogene fos: Complex but versatile regulation,</a>" Cell, 51:513-514 (1987).</td></tr><tr><td class="patent-data-table-td ">104</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Verma, et al., Proto Oncogene fos: Complex but versatile regulation, Cell, 51:513 514 (1987).</td></tr><tr><td class="patent-data-table-td ">105</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Visvader, et al., "<a href='http://scholar.google.com/scholar?q="Two+adjacent+promoter+elements+mediate+nerve+growth+factor+activation+of+the+c-fos+gene+and+bind+distinct+nuclear+complexes%2C"'>Two adjacent promoter elements mediate nerve growth factor activation of the c-fos gene and bind distinct nuclear complexes,</a>" PNAS, 85:9474-9478 (1988).</td></tr><tr><td class="patent-data-table-td ">106</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Visvader, et al., Two adjacent promoter elements mediate nerve growth factor activation of the c fos gene and bind distinct nuclear complexes, PNAS, 85:9474 9478 (1988).</td></tr><tr><td class="patent-data-table-td ">107</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wada, et al., "<a href='http://scholar.google.com/scholar?q="Functional+expression+of+a+new+pharmacological+subtype+of+brain+nicotinic+acetylcholine+receptor%2C"'>Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor,</a>" Science, 240:330-334 (1988).</td></tr><tr><td class="patent-data-table-td ">108</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Wada, et al., Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor, Science, 240:330 334 (1988).</td></tr><tr><td class="patent-data-table-td ">109</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ymer, et al., "<a href='http://scholar.google.com/scholar?q="GABAA+receptor+%CE%B2+subunit+heterogeneity%3A+functional+expression+of+cloned+cDNAs%2C"'>GABAA receptor β subunit heterogeneity: functional expression of cloned cDNAs,</a>" EMBO J., 8:1665-1670 (1989).</td></tr><tr><td class="patent-data-table-td ">110</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ymer, et al., GABA A receptor subunit heterogeneity: functional expression of cloned cDNAs, EMBO J., 8:1665 1670 (1989).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5739029">US5739029</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 15, 1995</td><td class="patent-data-table-td patent-date-value">Apr 14, 1998</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Vectors for expression of G protein coupled receptors in yeast</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5801232">US5801232</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 20, 1995</td><td class="patent-data-table-td patent-date-value">Sep 1, 1998</td><td class="patent-data-table-td ">Sibia Neuroscience, Inc.</td><td class="patent-data-table-td ">DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor alpha-2 subunit and cells transformed with same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5804436">US5804436</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 2, 1996</td><td class="patent-data-table-td patent-date-value">Sep 8, 1998</td><td class="patent-data-table-td ">Axiom Biotechnologies, Inc.</td><td class="patent-data-table-td ">Homogeneous suspension of living cells combined with a concentration of test compounds directed through a detection zone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5811231">US5811231</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 21, 1994</td><td class="patent-data-table-td patent-date-value">Sep 22, 1998</td><td class="patent-data-table-td ">Pres. And Fellows Of Harvard College</td><td class="patent-data-table-td ">Methods and kits for eukaryotic gene profiling</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5837489">US5837489</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 5, 1995</td><td class="patent-data-table-td patent-date-value">Nov 17, 1998</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Isolated nucleic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5849895">US5849895</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 20, 1994</td><td class="patent-data-table-td patent-date-value">Dec 15, 1998</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5856155">US5856155</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 23, 1996</td><td class="patent-data-table-td patent-date-value">Jan 5, 1999</td><td class="patent-data-table-td ">The Johns Hopkins University School Of Medicine</td><td class="patent-data-table-td ">Nucleic acid which encodes a polypeptide consisting of a core region of a .beta.-subunit of a shaker-like potassium ion channel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5910582">US5910582</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 16, 1996</td><td class="patent-data-table-td patent-date-value">Jun 8, 1999</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Human neuronal nicotinic acetylcholine receptor compositions and methods employing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5912132">US5912132</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 20, 1997</td><td class="patent-data-table-td patent-date-value">Jun 15, 1999</td><td class="patent-data-table-td ">Acadia Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Test kit contains culture of frozen cells transfected with dna coding for receptors and marker gene, a growth medium, and a reagent for marker detection; for screening ligand libraries</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5919646">US5919646</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 1, 1997</td><td class="patent-data-table-td patent-date-value">Jul 6, 1999</td><td class="patent-data-table-td ">Axiom Biotechnologies, Inc.</td><td class="patent-data-table-td ">Apparatus and method for real-time measurement of cellular response</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5922549">US5922549</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 27, 1994</td><td class="patent-data-table-td patent-date-value">Jul 13, 1999</td><td class="patent-data-table-td ">Boehringer Ingelheim International Gmbh</td><td class="patent-data-table-td ">Process for screening substances having a modulating effect on an interleukin-5 receptor mediated cellular signal transmission pathway</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5928888">US5928888</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 26, 1996</td><td class="patent-data-table-td patent-date-value">Jul 27, 1999</td><td class="patent-data-table-td ">Aurora Biosciences Corporation</td><td class="patent-data-table-td ">Using eukaryotic cell with beta-lactamase expression construct inserted into genome, contacting cell with exogenous protein, deleting enzyme activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5955281">US5955281</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 7, 1997</td><td class="patent-data-table-td patent-date-value">Sep 21, 1999</td><td class="patent-data-table-td ">Acadia Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Screening cells for mutant forms of receptors or signal transduction proteins by transfecting cells with dna library, incubating cells with little or no agonist, measuring levels of marker</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5958703">US5958703</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 3, 1996</td><td class="patent-data-table-td patent-date-value">Sep 28, 1999</td><td class="patent-data-table-td ">Glaxo Group Limited</td><td class="patent-data-table-td ">Screening complexes of test compound, a tag recording at least one step in the synthesis of the compound, and a tether sensitive to produced reporter molecule; separating complexes with modified tethers; decoding tag</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5972621">US5972621</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 22, 1996</td><td class="patent-data-table-td patent-date-value">Oct 26, 1999</td><td class="patent-data-table-td ">Millennium Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Incubating a cell that expresses an obr protein encoded by an exogenous nucleic acid molecule in the presence and absence of a test compound; determining phosphorylation, identifying compounds that alter phosphorylation; obesity, cachexia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5972639">US5972639</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 24, 1997</td><td class="patent-data-table-td patent-date-value">Oct 26, 1999</td><td class="patent-data-table-td ">Irori</td><td class="patent-data-table-td ">Screening for modulators by incubating cell lysate at acid ph with benzothiazole substrate, raising ph above 7, measuring fluorescence as indicator; for angiogenesis inhibitors, antitumor agents, treatment of vision defects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5981193">US5981193</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 3, 1991</td><td class="patent-data-table-td patent-date-value">Nov 9, 1999</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Human neuronal nicotinic acetylcholine receptor compositions and methods employing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5985586">US5985586</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td patent-date-value">Nov 16, 1999</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Methods for identifying compounds that modulate the activity of human N-methyl-D-aspartate receptors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5989835">US5989835</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 27, 1997</td><td class="patent-data-table-td patent-date-value">Nov 23, 1999</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">Automated monitoring of fluorescence; analyzing using computer; data processing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6001816">US6001816</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 19, 1997</td><td class="patent-data-table-td patent-date-value">Dec 14, 1999</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Gene therapy for leptin deficiency</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6004808">US6004808</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 19, 1997</td><td class="patent-data-table-td patent-date-value">Dec 21, 1999</td><td class="patent-data-table-td ">Aurora Biosciences Corporation</td><td class="patent-data-table-td ">Promiscuous G-protein compositions and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6007998">US6007998</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 21, 1997</td><td class="patent-data-table-td patent-date-value">Dec 28, 1999</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">A trans-activation screening method quantifying leptin receptor binding agents present in sample by determining if transcription of a reporter gene linked to a leptin response element occurs by contacting cells with sample; obesity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6013474">US6013474</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 27, 1997</td><td class="patent-data-table-td patent-date-value">Jan 11, 2000</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Calcium channel compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6022704">US6022704</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 5, 1995</td><td class="patent-data-table-td patent-date-value">Feb 8, 2000</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Nucleic acid sequences coding mammalian neuron receptor; for detection of modulators of receptor activity; for treatment of brain disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6033865">US6033865</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td patent-date-value">Mar 7, 2000</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Human n-methyl-d-aspartate receptor type 1 subunits, DNA encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6090623">US6090623</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 14, 1997</td><td class="patent-data-table-td patent-date-value">Jul 18, 2000</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Nucleotide sequences which code receptors associated with ionic mobility; for the detection of genetic defects associated with ionic mobility; for detection of modulators of ionic mobility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6091018">US6091018</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 1998</td><td class="patent-data-table-td patent-date-value">Jul 18, 2000</td><td class="patent-data-table-td ">Jx Crystals Inc.</td><td class="patent-data-table-td ">Three-layer solid infrared emitter with spectral output matched to low bandgap thermophotovoltaic cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6096514">US6096514</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 25, 1995</td><td class="patent-data-table-td patent-date-value">Aug 1, 2000</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Human calcium channel compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6111091">US6111091</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 29, 1997</td><td class="patent-data-table-td patent-date-value">Aug 29, 2000</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Nucleotide sequence of ionotropic glutamate receptor; probes to identify and isolate related human receptor subunits; drug screening assays to identify agonists, antagonists, and modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6159705">US6159705</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 24, 1997</td><td class="patent-data-table-td patent-date-value">Dec 12, 2000</td><td class="patent-data-table-td ">Cadus Pharmaceutical Corporation</td><td class="patent-data-table-td ">Screening by using yeast cell which expresses a heterologous receptor which is functionally integrated into an endogenous yeast signaling pathway, contacting with a test compound, and detecting alteration in signal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6168927">US6168927</a></td><td class="patent-data-table-td patent-date-value">Apr 8, 1998</td><td class="patent-data-table-td patent-date-value">Jan 2, 2001</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Expression of G protein coupled receptors in yeast</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6221578">US6221578</a></td><td class="patent-data-table-td patent-date-value">Jan 24, 1997</td><td class="patent-data-table-td patent-date-value">Apr 24, 2001</td><td class="patent-data-table-td ">Virco N.V.</td><td class="patent-data-table-td ">Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6221617">US6221617</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 1997</td><td class="patent-data-table-td patent-date-value">Apr 24, 2001</td><td class="patent-data-table-td ">Julie Heinrich</td><td class="patent-data-table-td ">Bioassay for growth hormone releasing hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6242209">US6242209</a></td><td class="patent-data-table-td patent-date-value">May 10, 2000</td><td class="patent-data-table-td patent-date-value">Jun 5, 2001</td><td class="patent-data-table-td ">Axiom Biotechnologies, Inc.</td><td class="patent-data-table-td ">Cell flow apparatus and method for real-time measurements of cellular responses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6251605">US6251605</a></td><td class="patent-data-table-td patent-date-value">Oct 25, 1999</td><td class="patent-data-table-td patent-date-value">Jun 26, 2001</td><td class="patent-data-table-td ">Cadus Pharmaceutical Corporation</td><td class="patent-data-table-td ">Yeast cells having mutations in Cav1 and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6255059">US6255059</a></td><td class="patent-data-table-td patent-date-value">Jan 17, 1996</td><td class="patent-data-table-td patent-date-value">Jul 3, 2001</td><td class="patent-data-table-td ">Cadus Pharmaceutical Corporation</td><td class="patent-data-table-td ">Methods for identifying G protein coupled receptor effectors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6280967">US6280967</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 1999</td><td class="patent-data-table-td patent-date-value">Aug 28, 2001</td><td class="patent-data-table-td ">Axiom Biotechnologies, Inc.</td><td class="patent-data-table-td ">Detecting particles which generate cellular response; mix cell suspension with modulators, pass through detection zone and measure preferential cellular responses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6303310">US6303310</a></td><td class="patent-data-table-td patent-date-value">Jul 21, 1999</td><td class="patent-data-table-td patent-date-value">Oct 16, 2001</td><td class="patent-data-table-td ">Guilford Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Screening library for peptides or proteins with preferential functions; provide cells and plasmid, transform cells, detect and monitor protein interactions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6303753">US6303753</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 1998</td><td class="patent-data-table-td patent-date-value">Oct 16, 2001</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human neuronal nicotinic acetylcholine receptor compositions and methods employing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6309842">US6309842</a></td><td class="patent-data-table-td patent-date-value">Nov 24, 1997</td><td class="patent-data-table-td patent-date-value">Oct 30, 2001</td><td class="patent-data-table-td ">Glaxo Wellcome Inc.</td><td class="patent-data-table-td ">Use of modified tethers in screening compound libraries</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6309889">US6309889</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 1999</td><td class="patent-data-table-td patent-date-value">Oct 30, 2001</td><td class="patent-data-table-td ">Glaxo Wellcome Inc.</td><td class="patent-data-table-td ">Nano-grid micro reactor and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6316611">US6316611</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 1997</td><td class="patent-data-table-td patent-date-value">Nov 13, 2001</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6355473">US6355473</a></td><td class="patent-data-table-td patent-date-value">May 5, 1999</td><td class="patent-data-table-td patent-date-value">Mar 12, 2002</td><td class="patent-data-table-td ">Cadus Pharmaceutical Corp.</td><td class="patent-data-table-td ">Yeast cells having mutations in stp22 and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6362009">US6362009</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 1997</td><td class="patent-data-table-td patent-date-value">Mar 26, 2002</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Solid phase synthesis of heterocycles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6376660">US6376660</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 1997</td><td class="patent-data-table-td patent-date-value">Apr 23, 2002</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6387696">US6387696</a></td><td class="patent-data-table-td patent-date-value">May 25, 1995</td><td class="patent-data-table-td patent-date-value">May 14, 2002</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human calcium channel compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6403766">US6403766</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 1999</td><td class="patent-data-table-td patent-date-value">Jun 11, 2002</td><td class="patent-data-table-td ">Cornell Research Foundation, Inc.</td><td class="patent-data-table-td ">Isolated human actin-binding regulatory protein expressed in motile, proliferating and invasive cells and in cells at wound sites</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6440681">US6440681</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Aug 27, 2002</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Using isolated dnas encoding human alpha and beta subunits of the receptors and the polypeptides encoded thereby; measuring ion flux, electrophysiological response; drug screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6469142">US6469142</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2000</td><td class="patent-data-table-td patent-date-value">Oct 22, 2002</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Components of nmda receptors that have cation-selective channels and bind glutamate and nmda (n-methyl-d-aspartate)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6485922">US6485922</a></td><td class="patent-data-table-td patent-date-value">Oct 9, 1998</td><td class="patent-data-table-td patent-date-value">Nov 26, 2002</td><td class="patent-data-table-td ">Atairgin Technologies, Inc.</td><td class="patent-data-table-td ">Methods for detecting compounds which modulate the activity of an LPA receptor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6485967">US6485967</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Nov 26, 2002</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6504008">US6504008</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 1999</td><td class="patent-data-table-td patent-date-value">Jan 7, 2003</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Cell based signal generation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6521413">US6521413</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 1999</td><td class="patent-data-table-td patent-date-value">Feb 18, 2003</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Bioassay; monitoring cells for changes in ion channel activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6524789">US6524789</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1996</td><td class="patent-data-table-td patent-date-value">Feb 25, 2003</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human neuronal nicotinic acetylcholine receptor compositions and methods employing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6528251">US6528251</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2000</td><td class="patent-data-table-td patent-date-value">Mar 4, 2003</td><td class="patent-data-table-td ">Virco N.V.</td><td class="patent-data-table-td ">Transfecting a cell line susceptible to infection by HIV with a sequence from the pol gene of HIV, which sequence encodes a desired target enzyme</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6555325">US6555325</a></td><td class="patent-data-table-td patent-date-value">Jun 12, 2000</td><td class="patent-data-table-td patent-date-value">Apr 29, 2003</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Kit for screening of test compounds that modulate a heterologous G protein-coupled receptor in a yeast cell uses a mixture of yeast cells; modulators of heterologous receptors coupled to the pheromone response pathway in yeast</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6558916">US6558916</a></td><td class="patent-data-table-td patent-date-value">Feb 7, 2001</td><td class="patent-data-table-td patent-date-value">May 6, 2003</td><td class="patent-data-table-td ">Axiom Biotechnologies, Inc.</td><td class="patent-data-table-td ">Cell flow apparatus and method for real-time measurements of patient cellular responses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6573039">US6573039</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2000</td><td class="patent-data-table-td patent-date-value">Jun 3, 2003</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">Automated method for analyzing translocation of a protein between nucleus and cytoplasm using fluorescent reporter molecules; use in drug screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6579675">US6579675</a></td><td class="patent-data-table-td patent-date-value">May 26, 1999</td><td class="patent-data-table-td patent-date-value">Jun 17, 2003</td><td class="patent-data-table-td ">Deltagen Proteomics, Inc.</td><td class="patent-data-table-td ">Methods for identifying nucleic acid sequences encoding agents that effect cellular phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6607906">US6607906</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 1998</td><td class="patent-data-table-td patent-date-value">Aug 19, 2003</td><td class="patent-data-table-td ">Basf Aktiengesellschaft</td><td class="patent-data-table-td ">Use in assaying compounds to determine effects on cell growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6620585">US6620585</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2000</td><td class="patent-data-table-td patent-date-value">Sep 16, 2003</td><td class="patent-data-table-td ">Elitra Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Use of ectoenzymes and secreted enzymes to monitor cellular proliferation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6620591">US6620591</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 1999</td><td class="patent-data-table-td patent-date-value">Sep 16, 2003</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6623922">US6623922</a></td><td class="patent-data-table-td patent-date-value">Feb 14, 1997</td><td class="patent-data-table-td patent-date-value">Sep 23, 2003</td><td class="patent-data-table-td ">Deltagen Proteomics</td><td class="patent-data-table-td ">Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6632625">US6632625</a></td><td class="patent-data-table-td patent-date-value">Dec 2, 1997</td><td class="patent-data-table-td patent-date-value">Oct 14, 2003</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Ob (obesity gene); receptors may be used in various assays, such as a transactivation assay to identify novel ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6653097">US6653097</a></td><td class="patent-data-table-td patent-date-value">May 25, 1995</td><td class="patent-data-table-td patent-date-value">Nov 25, 2003</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human calcium channel compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6664375">US6664375</a></td><td class="patent-data-table-td patent-date-value">Jun 27, 2001</td><td class="patent-data-table-td patent-date-value">Dec 16, 2003</td><td class="patent-data-table-td ">Kathryn J. Elliott</td><td class="patent-data-table-td ">Nucleotide sequences coding binding protein for use in the treatment of alzheimer&#39;s disease and nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6671624">US6671624</a></td><td class="patent-data-table-td patent-date-value">Nov 27, 2000</td><td class="patent-data-table-td patent-date-value">Dec 30, 2003</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">Machine readable storage media for detecting distribution of macromolecules between nucleus and cytoplasm in cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6689559">US6689559</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Feb 10, 2004</td><td class="patent-data-table-td ">The Research Foundation Of The State University Of New York</td><td class="patent-data-table-td ">Efficient hepatitis C virus replicon and its use in identifying antiviral compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6716588">US6716588</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 2000</td><td class="patent-data-table-td patent-date-value">Apr 6, 2004</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6727071">US6727071</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 1998</td><td class="patent-data-table-td patent-date-value">Apr 27, 2004</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6780974">US6780974</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 2001</td><td class="patent-data-table-td patent-date-value">Aug 24, 2004</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">Synthetic DNA encoding an orange seapen-derived green fluorescent protein with codon preference of mammalian expression systems and biosensors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6825322">US6825322</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2002</td><td class="patent-data-table-td patent-date-value">Nov 30, 2004</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6838239">US6838239</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2000</td><td class="patent-data-table-td patent-date-value">Jan 4, 2005</td><td class="patent-data-table-td ">San Diego State University Foundation</td><td class="patent-data-table-td ">Chitobiase as a reporter enzyme</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6838249">US6838249</a></td><td class="patent-data-table-td patent-date-value">Mar 28, 2003</td><td class="patent-data-table-td patent-date-value">Jan 4, 2005</td><td class="patent-data-table-td ">Sui-Po Zhang</td><td class="patent-data-table-td ">Identifying transport protein modulator using gabapentin (GBP) as a transfer/fluid flow indicator; anticonvulsant; neuropathic pain</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6852546">US6852546</a></td><td class="patent-data-table-td patent-date-value">Mar 30, 2000</td><td class="patent-data-table-td patent-date-value">Feb 8, 2005</td><td class="patent-data-table-td ">Diagnostic Hybrids, Inc.</td><td class="patent-data-table-td ">Diagnosis of autoimmune disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6855550">US6855550</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 2000</td><td class="patent-data-table-td patent-date-value">Feb 15, 2005</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Genetically engineered microorganism for use as tools in the generation of heterologous binding proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6864060">US6864060</a></td><td class="patent-data-table-td patent-date-value">Oct 7, 1997</td><td class="patent-data-table-td patent-date-value">Mar 8, 2005</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Yeast cells expressing modified G proteins and methods of use therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6864358">US6864358</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2001</td><td class="patent-data-table-td patent-date-value">Mar 8, 2005</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6902883">US6902883</a></td><td class="patent-data-table-td patent-date-value">May 6, 2003</td><td class="patent-data-table-td patent-date-value">Jun 7, 2005</td><td class="patent-data-table-td ">R. Terry Dunlay</td><td class="patent-data-table-td ">Microtiter plates comprising fluorescent reporter; bioinformatics; drug screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6929925">US6929925</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2000</td><td class="patent-data-table-td patent-date-value">Aug 16, 2005</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Assays for sensory modulators using a sensory cell specific G-protein beta subunit</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6956102">US6956102</a></td><td class="patent-data-table-td patent-date-value">Sep 4, 2001</td><td class="patent-data-table-td patent-date-value">Oct 18, 2005</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human N-methyl-D-aspartate receptor subunits nucleic acids encoding same and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6958221">US6958221</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2002</td><td class="patent-data-table-td patent-date-value">Oct 25, 2005</td><td class="patent-data-table-td ">Caliper Life Sciences, Inc.</td><td class="patent-data-table-td ">Determining the effect of each of a plurality of test agents on cells from a subject, and a method to profile patient cell responses to test agents.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6979547">US6979547</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 1999</td><td class="patent-data-table-td patent-date-value">Dec 27, 2005</td><td class="patent-data-table-td ">Cornell Research Foundation, Inc.</td><td class="patent-data-table-td ">Methods for designing specific ion channel blockers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6986993">US6986993</a></td><td class="patent-data-table-td patent-date-value">Nov 20, 2000</td><td class="patent-data-table-td patent-date-value">Jan 17, 2006</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">High-speed fluorescence-based cell and molecular biochemical assays for drug discovery; optical imaging of cells containing fluorescent reporter molecules, converting to digital data and interpreting the data; automatic</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7022513">US7022513</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2002</td><td class="patent-data-table-td patent-date-value">Apr 4, 2006</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Signal transduction; screening bactericides, viricides, fungicides, parasiticides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7045599">US7045599</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 2004</td><td class="patent-data-table-td patent-date-value">May 16, 2006</td><td class="patent-data-table-td ">Prolume Ltd.</td><td class="patent-data-table-td ">Synthetic DNA encoding an orange seapen-derived green fluorescent protein with codon preference of mammalian expression systems and biosensors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7049084">US7049084</a></td><td class="patent-data-table-td patent-date-value">May 30, 2001</td><td class="patent-data-table-td patent-date-value">May 23, 2006</td><td class="patent-data-table-td ">Ortho-Mcneil Pharmaceutical, Inc.</td><td class="patent-data-table-td ">Neuroblastoma cell lines expressing the α2δ subunit of calcium channels and methods therefore</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7060445">US7060445</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2000</td><td class="patent-data-table-td patent-date-value">Jun 13, 2006</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7081360">US7081360</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 1999</td><td class="patent-data-table-td patent-date-value">Jul 25, 2006</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7090991">US7090991</a></td><td class="patent-data-table-td patent-date-value">Mar 31, 2003</td><td class="patent-data-table-td patent-date-value">Aug 15, 2006</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">System for detection of a functional interaction between a compound and a cellular signal transduction component</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7105309">US7105309</a></td><td class="patent-data-table-td patent-date-value">Oct 1, 2002</td><td class="patent-data-table-td patent-date-value">Sep 12, 2006</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Yeast cells engineered to produce pheromone system protein surrogates and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7105313">US7105313</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2003</td><td class="patent-data-table-td patent-date-value">Sep 12, 2006</td><td class="patent-data-table-td ">Amgen Inc.</td><td class="patent-data-table-td ">Contacting mammal cell with mutant coding reporter molecule; calibration gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7117098">US7117098</a></td><td class="patent-data-table-td patent-date-value">Nov 27, 2000</td><td class="patent-data-table-td patent-date-value">Oct 3, 2006</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">Machine-readable storage medium for analyzing distribution of macromolecules between the cell membrane and the cell cytoplasm</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7122305">US7122305</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2000</td><td class="patent-data-table-td patent-date-value">Oct 17, 2006</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Methods and compositions for identifying receptor effectors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7148053">US7148053</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2002</td><td class="patent-data-table-td patent-date-value">Dec 12, 2006</td><td class="patent-data-table-td ">Basf Aktiengesellschaft</td><td class="patent-data-table-td ">Transgenic yeast cells coding membrane receptor proteins for diagnosis and treatment of pancreatitis, pancreatic cancer, gastrointestinal disorders and irritable bowel disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7157243">US7157243</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 6, 2000</td><td class="patent-data-table-td patent-date-value">Jan 2, 2007</td><td class="patent-data-table-td ">Neuromed Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">DNA encoding mammalian T-type calcium channels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7223533">US7223533</a></td><td class="patent-data-table-td patent-date-value">Dec 1, 2003</td><td class="patent-data-table-td patent-date-value">May 29, 2007</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7235373">US7235373</a></td><td class="patent-data-table-td patent-date-value">Apr 11, 2003</td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7235648">US7235648</a></td><td class="patent-data-table-td patent-date-value">Feb 26, 1999</td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7238497">US7238497</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 2004</td><td class="patent-data-table-td patent-date-value">Jul 3, 2007</td><td class="patent-data-table-td ">Prolume, Ltd.</td><td class="patent-data-table-td ">Synthetic DNA encoding an orange seapen-derived green fluorescent protein with codon preference of mammalian expression systems and biosensors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7250263">US7250263</a></td><td class="patent-data-table-td patent-date-value">Jan 5, 2004</td><td class="patent-data-table-td patent-date-value">Jul 31, 2007</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Methods and compositions for identifying receptor effectors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7273747">US7273747</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2002</td><td class="patent-data-table-td patent-date-value">Sep 25, 2007</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Cell having amplified signal transduction pathway responses and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7297504">US7297504</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 1999</td><td class="patent-data-table-td patent-date-value">Nov 20, 2007</td><td class="patent-data-table-td ">Neuromed Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Methods for identifying agonists and antagonists of human T-type calcium channels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7319009">US7319009</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 2002</td><td class="patent-data-table-td patent-date-value">Jan 15, 2008</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Genetically engineered cell coding G protein coupled formyl peptide orphan receptor (FPRL-1) for monitoring adjustment in chemotaxis and cell respiratory activity; drug screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7361498">US7361498</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 2004</td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td ">Cadus Technologies, Inc.</td><td class="patent-data-table-td ">Transgenic yeast comprising g-protein coupled orphan receptors for use as tools in identifying ion channel modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7413876">US7413876</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 2004</td><td class="patent-data-table-td patent-date-value">Aug 19, 2008</td><td class="patent-data-table-td ">Duke University Office Of Science And Technology</td><td class="patent-data-table-td ">Expression of G protein coupled receptors in yeast</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7414110">US7414110</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 2007</td><td class="patent-data-table-td patent-date-value">Aug 19, 2008</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Human calcium channel compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7425420">US7425420</a></td><td class="patent-data-table-td patent-date-value">Mar 16, 2005</td><td class="patent-data-table-td patent-date-value">Sep 16, 2008</td><td class="patent-data-table-td ">Acadia Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Using g-protein coupled receptor to identify modulators for prevention and treatment of schizophrenia and related psychoses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452682">US7452682</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 3, 2006</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Acadia Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Identification of 5HT2A receptor ligands by selective amplification of cells transfected with receptors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7470536">US7470536</a></td><td class="patent-data-table-td patent-date-value">Oct 3, 2003</td><td class="patent-data-table-td patent-date-value">Dec 30, 2008</td><td class="patent-data-table-td ">Neutekbio Limited</td><td class="patent-data-table-td ">Transgenic cell line for use as tools in identification of signal transduction modulators; diagnostic assay comprising enhanced shelf life</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7491503">US7491503</a></td><td class="patent-data-table-td patent-date-value">May 3, 2006</td><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td ">Acadia Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Identification of ligands by selective amplification of cells transfected with receptors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7501263">US7501263</a></td><td class="patent-data-table-td patent-date-value">Jan 3, 2007</td><td class="patent-data-table-td patent-date-value">Mar 10, 2009</td><td class="patent-data-table-td ">Neuromed Technologies, Inc.</td><td class="patent-data-table-td ">Nucleic acids encoding mammalian T-type calcium channels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7517672">US7517672</a></td><td class="patent-data-table-td patent-date-value">Jan 3, 2007</td><td class="patent-data-table-td patent-date-value">Apr 14, 2009</td><td class="patent-data-table-td ">Neuromed Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Nucleic acids encoding mammalian T-type calcium channels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7853409">US7853409</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2007</td><td class="patent-data-table-td patent-date-value">Dec 14, 2010</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7887753">US7887753</a></td><td class="patent-data-table-td patent-date-value">May 27, 2008</td><td class="patent-data-table-td patent-date-value">Feb 15, 2011</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Apparatus and methods for conducting assays and high throughput screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8039233">US8039233</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2007</td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td ">Givaudan S.A.</td><td class="patent-data-table-td ">Nucleic acid sequences and their use in methods to identify umami modulatiors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8062856">US8062856</a></td><td class="patent-data-table-td patent-date-value">Sep 16, 2005</td><td class="patent-data-table-td patent-date-value">Nov 22, 2011</td><td class="patent-data-table-td ">Cellomics, Inc.</td><td class="patent-data-table-td ">System for cell-based screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8071323">US8071323</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2007</td><td class="patent-data-table-td patent-date-value">Dec 6, 2011</td><td class="patent-data-table-td ">The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services</td><td class="patent-data-table-td ">Human monoclonal antibodies that bind human insulin like growth factors and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8273574">US8273574</a></td><td class="patent-data-table-td patent-date-value">Feb 14, 2011</td><td class="patent-data-table-td patent-date-value">Sep 25, 2012</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Apparatus and methods for conducting assays and high throughput screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8426123">US8426123</a></td><td class="patent-data-table-td patent-date-value">Oct 29, 2008</td><td class="patent-data-table-td patent-date-value">Apr 23, 2013</td><td class="patent-data-table-td ">Biomonitor Limited</td><td class="patent-data-table-td ">Method for conducting an assay for neutralizing antibodies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8455258">US8455258</a></td><td class="patent-data-table-td patent-date-value">Feb 15, 2011</td><td class="patent-data-table-td patent-date-value">Jun 4, 2013</td><td class="patent-data-table-td ">California Insitute Of Technology</td><td class="patent-data-table-td ">Apparatus and methods for conducting assays and high throughput screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8642330">US8642330</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2006</td><td class="patent-data-table-td patent-date-value">Feb 4, 2014</td><td class="patent-data-table-td ">Onconon, Llc</td><td class="patent-data-table-td ">Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8673645">US8673645</a></td><td class="patent-data-table-td patent-date-value">Sep 4, 2012</td><td class="patent-data-table-td patent-date-value">Mar 18, 2014</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Apparatus and methods for conducting assays and high throughput screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759091">US8759091</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2007</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Le Centre National De La Recherche Scientifique</td><td class="patent-data-table-td ">Gene reporter assay, kit and cells with improved sensitivity and/or specificity for determining the level of an extracellular signal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0542830A1?cl=en">EP0542830A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by third party"> †</span></td><td class="patent-data-table-td patent-date-value">Aug 7, 1991</td><td class="patent-data-table-td patent-date-value">May 26, 1993</td><td class="patent-data-table-td ">Sibia Neurosciences, Inc.</td><td class="patent-data-table-td ">Assay methods and compositions for detecting and evaluating the intracellular transduction of an extracellular signal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0929665A1?cl=en">EP0929665A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 2, 1997</td><td class="patent-data-table-td patent-date-value">Jul 21, 1999</td><td class="patent-data-table-td ">Tularik, Inc.</td><td class="patent-data-table-td ">Cell-based drug screens for regulators of gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1167522A1?cl=en">EP1167522A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 10, 2000</td><td class="patent-data-table-td patent-date-value">Jan 2, 2002</td><td class="patent-data-table-td ">Ajinomoto Co., Inc.</td><td class="patent-data-table-td ">Method for screening biomolecule activity regulator</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2060628A1?cl=en">EP2060628A1</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2003</td><td class="patent-data-table-td patent-date-value">May 20, 2009</td><td class="patent-data-table-td ">XOMA Technology Ltd.</td><td class="patent-data-table-td ">Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2123761A2?cl=en">EP2123761A2</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2005</td><td class="patent-data-table-td patent-date-value">Nov 25, 2009</td><td class="patent-data-table-td ">Lonza Ag</td><td class="patent-data-table-td ">Rhamnose promoter expression system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2325294A2?cl=en">EP2325294A2</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 2001</td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td ">The Regents Of the University of California</td><td class="patent-data-table-td ">Visual-servoing optical microscopy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2381116A1?cl=en">EP2381116A1</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2001</td><td class="patent-data-table-td patent-date-value">Oct 26, 2011</td><td class="patent-data-table-td ">California Institute of Technology</td><td class="patent-data-table-td ">Apparatus and methods for conducting assays and high throughput screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995035501A1?cl=en">WO1995035501A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 16, 1995</td><td class="patent-data-table-td patent-date-value">Dec 28, 1995</td><td class="patent-data-table-td ">Univ Leland Stanford Junior</td><td class="patent-data-table-td ">Cell calcium regulation and its use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1997041154A1?cl=en">WO1997041154A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 24, 1997</td><td class="patent-data-table-td patent-date-value">Nov 6, 1997</td><td class="patent-data-table-td ">Merck &amp; Co Inc</td><td class="patent-data-table-td ">Eosinophil eotaxin receptor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998024881A1?cl=en">WO1998024881A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 26, 1997</td><td class="patent-data-table-td patent-date-value">Jun 11, 1998</td><td class="patent-data-table-td ">Tung M Fong</td><td class="patent-data-table-td ">Mutant ob receptors and nucleotides encoding them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000045179A2?cl=en">WO2000045179A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 26, 2000</td><td class="patent-data-table-td patent-date-value">Aug 3, 2000</td><td class="patent-data-table-td ">Adler Jon Elliot</td><td class="patent-data-table-td ">Screening for modulators of g-protein subunit beta 3</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2002097045A2?cl=en">WO2002097045A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 28, 2002</td><td class="patent-data-table-td patent-date-value">Dec 5, 2002</td><td class="patent-data-table-td ">Ortho Mcneil Pharm Inc</td><td class="patent-data-table-td ">Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003027634A2?cl=en">WO2003027634A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 23, 2002</td><td class="patent-data-table-td patent-date-value">Apr 3, 2003</td><td class="patent-data-table-td ">Axiom Biotechnologies Inc</td><td class="patent-data-table-td ">Identification of modulatory molecules using inducible promoters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007128230A1?cl=en">WO2007128230A1</a></td><td class="patent-data-table-td patent-date-value">Apr 29, 2007</td><td class="patent-data-table-td patent-date-value">Nov 15, 2007</td><td class="patent-data-table-td ">Heping Cheng</td><td class="patent-data-table-td ">Method and system for screening the receptor-ligand binding in live cell</td></tr></table><div class="patent-section-footer">* Cited by examiner, † Cited by third party</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S006160">435/6.16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc436/defs436.htm&usg=AFQjCNGx2wdEO-lMZYH5-JBwc-X_dDDKIg#C436S063000">436/63</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=G01N0033940000">G01N33/94</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=G01N0033680000">G01N33/68</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12Q0001680000">C12Q1/68</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014705000">C07K14/705</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014820000">C07K14/82</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12Q0001020000">C12Q1/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0005100000">C12N5/10</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/705">C07K14/705</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/82">C07K14/82</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=G01N33/9406">G01N33/9406</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12Q1/6897">C12Q1/6897</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=yYc7BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=G01N33/6872">G01N33/6872</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">G01N33/68F</span>, <span class="nested-value">G01N33/94B</span>, <span class="nested-value">C07K14/705</span>, <span class="nested-value">C07K14/82</span>, <span class="nested-value">C12Q1/68P</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">May 22, 2007</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070328</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 28, 2007</td><td class="patent-data-table-td ">LAPS</td><td class="patent-data-table-td ">Lapse for failure to pay maintenance fees</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 12, 2006</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 14, 2002</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 10, 2000</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERCK &amp; CO., INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIBIA NEUROSCIENCES, INC.;REEL/FRAME:010514/0001</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19991222</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERCK &amp; CO., INC. 126 LINCOLN AVENUE RAHWAY NEW JE</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 15, 1999</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19990412</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 15, 1998</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19981009</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 27, 1998</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 2, 1996</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SIBIA NEUROSCIENCES, INC., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC., THE;REEL/FRAME:008094/0461</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19960318</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 14, 1996</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 21, 1990</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BRUST, PAUL;HARPOLD, MICHAEL M.;REEL/FRAME:005464/0981;SIGNING DATES FROM 19900906 TO 19900914</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2VCCrag6pWmYduqkvQLTAElgvXtg\u0026id=yYc7BAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0Iu6L_3zeV5yP6jh9ToMIPo3llpg\u0026id=yYc7BAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U20UTTPXCm3-94T0UsKWgqv3oAyZw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Assay_methods_and_compositions_useful_fo.pdf?id=yYc7BAABERAJ\u0026output=pdf\u0026sig=ACfU3U2OE_WCRaBL2WnWA3KWnrM9labZPw"},"sample_url":"http://www.google.com/patents/reader?id=yYc7BAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>